Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA.
Tosyl compounds are organic derivatives characterized by the introduction of a tosyl group, which is the sulfonate ester of p-toluenesulfonic acid (CH3C6H4SO3H), into an organic molecule through a substitution reaction.
An agent with anti-androgen and progestational properties. It shows competitive binding with dihydrotestosterone at androgen receptor sites.
A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.
Anilides are organic compounds resulting from the reaction of aniline (a primary aromatic amine) with carboxylic acids or their derivatives, forming amides, which have various applications in pharmaceuticals and agrochemicals.
Tumors or cancer of the PROSTATE.
Compounds that bind to and inhibit the activation of ANDROGEN RECEPTORS.
A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.
Steroidal compounds related to TESTOSTERONE, the major mammalian male sex hormone. Testosterone congeners include important testosterone precursors in the biosynthetic pathways, metabolites, derivatives, and synthetic steroids with androgenic activities.
A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.
Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.
A disorder of sexual development transmitted as an X-linked recessive trait. These patients have a karyotype of 46,XY with end-organ resistance to androgen due to mutations in the androgen receptor (RECEPTORS, ANDROGEN) gene. Severity of the defect in receptor quantity or quality correlates with their phenotypes. In these genetic males, the phenotypic spectrum ranges from those with normal female external genitalia, through those with genital ambiguity as in Reifenstein Syndrome, to that of a normal male with INFERTILITY.
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists.
Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS.
Agents inhibiting the effect of narcotics on the central nervous system.
Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM.
A ligand that binds to but fails to activate the INTERLEUKIN 1 RECEPTOR. It plays an inhibitory role in the regulation of INFLAMMATION and FEVER. Several isoforms of the protein exist due to multiple ALTERNATIVE SPLICING of its mRNA.
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
Drugs that bind to but do not activate GABA RECEPTORS, thereby blocking the actions of endogenous GAMMA-AMINOBUTYRIC ACID and GABA RECEPTOR AGONISTS.
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood.
A family of hexahydropyridines.
Compounds that bind to and block the stimulation of PURINERGIC P1 RECEPTORS.
A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.
Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only.
Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
Compounds that selectively bind to and block the activation of ADENOSINE A2 RECEPTORS.
Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.
Compounds that bind to and block the stimulation of PURINERGIC P2 RECEPTORS.
C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.
The unspecified form of the steroid, normally a major metabolite of TESTOSTERONE with androgenic activity. It has been implicated as a regulator of gonadotropin secretion.
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS.
Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.
An enzyme that catalyzes the reduction of TESTOSTERONE to 5-ALPHA DIHYDROTESTOSTERONE.
A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.
A cell line derived from cultured tumor cells.
Compounds that bind to and block the stimulation of ADENOSINE A1 RECEPTORS.
A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.
Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.
Drugs that bind to and block the activation of ADRENERGIC ALPHA-2 RECEPTORS.
A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.
Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE.
Drugs that bind to but do not activate GABA-A RECEPTORS thereby blocking the actions of endogenous or exogenous GABA-A RECEPTOR AGONISTS.
Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.
The male gonad containing two functional parts: the SEMINIFEROUS TUBULES for the production and transport of male germ cells (SPERMATOGENESIS) and the interstitial compartment containing LEYDIG CELLS that produce ANDROGENS.
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.
Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders).
Drugs that selectively bind to but do not activate HISTAMINE H3 RECEPTORS. They have been used to correct SLEEP WAKE DISORDERS and MEMORY DISORDERS.
A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)
A microsomal cytochrome P450 enzyme that catalyzes the 17-alpha-hydroxylation of progesterone or pregnenolone and subsequent cleavage of the residual two carbons at C17 in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP17 gene, generates precursors for glucocorticoid, androgen, and estrogen synthesis. Defects in CYP17 gene cause congenital adrenal hyperplasia (ADRENAL HYPERPLASIA, CONGENITAL) and abnormal sexual differentiation.
The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.
An enzyme that catalyzes the desaturation (aromatization) of the ring A of C19 androgens and converts them to C18 estrogens. In this process, the 19-methyl is removed. This enzyme is membrane-bound, located in the endoplasmic reticulum of estrogen-producing cells of ovaries, placenta, testes, adipose, and brain tissues. Aromatase is encoded by the CYP19 gene, and functions in complex with NADPH-FERRIHEMOPROTEIN REDUCTASE in the cytochrome P-450 system.
Elements of limited time intervals, contributing to particular results or situations.
Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action.
Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.
Cell surface proteins that bind ENDOTHELINS with high affinity and trigger intracellular changes which influence the behavior of cells.
An oxidoreductase that catalyzes the conversion of 3-oxo-delta4 steroids into their corresponding 5alpha form. It plays an important role in the conversion of TESTOSTERONE into DIHYDROTESTOSTERONE and PROGESTERONE into DIHYDROPROGESTERONE.
Drugs that bind to and block the activation of ADRENERGIC BETA-2 RECEPTORS.
A class of ionotropic glutamate receptors characterized by affinity for N-methyl-D-aspartate. NMDA receptors have an allosteric binding site for glycine which must be occupied for the channel to open efficiently and a site within the channel itself to which magnesium ions bind in a voltage-dependent manner. The positive voltage dependence of channel conductance and the high permeability of the conducting channel to calcium ions (as well as to monovalent cations) are important in excitotoxicity and neuronal plasticity.

The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. (1/1203)

We have examined five human breast cancer cell lines in continuous tissue culture for androgen responsiveness. One of these cell lines shows a 2- to 4-fold stimulation of thymidine incorporation into DNA, apparent as early as 10 hr following androgen addition to cells incubated in serum-free medium. This stimulation is accompanied by an acceleration in cell replication. Antiandrogens [cyproterone acetate (6-chloro-17alpha-acetate-1,2alpha-methylene-4,6-pregnadiene-3,20-dione) and R2956 (17beta-hydroxy-2,2,17alpha-trimethoxyestra-4,9,11-triene-1-one)] inhibit both protein and DNA synthesis below control levels and block androgen-mediated stimulation. Prolonged incubation (greater than 72 hr) in antiandrogen is lethal. The MCF- cell line contains high-affinity receptors for androgenic steroids demonstrable by sucrose density gradients and competitive protein binding analysis. By cross-competition studies, androgen receptors are distinguishable from estrogen receptors also found in this cell line. Concentrations of steroid that saturate androgen receptor sites in vitro are about 1000 times lower than concentrations that maximally stimulate the cells. Changes in quantity and affinity of androgen binding to intact cells at 37 degrees as compared with usual binding techniques using cytosol preparation at 0 degrees do not explain this difference between dissociation of binding and effect. However, this difference can be explained by conversion of [3H]-5alpha-dihydrotestosterone to 5alpha-androstanediol and more polar metabolites at 37 degrees. An examination of incubation media, cytoplasmic extracts and crude nuclear pellets reveals probable conversion of [3H]testosterone to [3H]-5alpha-dihydrotestosterone. Our data provide compelling evidence that some human breast cancer, at least in vitro, may be androgen dependent.  (+info)

Pharmacokinetics of flutamide in patients with renal insufficiency. (2/1203)

AIMS: The aim of this study was to determine the pharmacokinetic parameters of flutamide, a nonsteroidal antiandrogenic compound, and its pharmacologically active metabolite, hydroxyflutamide, in renal insufficiency. Haemodialysis (HD) clearance of flutamide and hydroxyflutamide was also determined. METHODS: Pharmacokinetic parameters were assessed for flutamide and hydroxyflutamide in 26 male subjects with normal renal function (creatinine clearance by 24 h urine collection, CLcr, greater than 80 ml min(-1) 1.73 m(-2); n=6) or reduced renal function; CLcr=50-80 (n=7), 30-49 (n=3), 5-29 (n=4), and <5 ml min(-1) 1.73 m(-2)-HD (n=6), following a single, oral 250 mg flutamide dose. Subjects undergoing HD received a second 250 mg dose of flutamide 4 h prior to HD; blood and dialysate were collected during HD to determine dialysability of flutamide and hydroxyflutamide. RESULTS: Cmax, tmax, AUC, t1/2, and renal clearance of flutamide and hydroxyflutamide did not differ between groups. Less than 1% of the dose appeared in dialysate as hydroxyflutamide. No serious adverse events were observed. CONCLUSIONS: Renal function did not affect flutamide nor hydroxyflutamide disposition. HD did not alter hydroxyflutamide pharmacokinetics. Dosing adjustments for renal impairment or HD are not indicated for flutamide.  (+info)

Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. (3/1203)

Transcription of the prostate-specific antigen (PSA) gene escapes regulation by androgens in advanced prostate cancer. To determine the molecular mechanism(s) of androgen-independent regulation of the PSA gene, the possibility that the androgen receptor (AR) is activated in the absence of androgen by stimulation of protein kinase A (PKA) was investigated. Activation of PKA by forskolin resulted in elevated expression of the PSA gene in androgen-depleted LNCaP cells, an effect that was blocked by the antiandrogen, bicalutamide. Further evidence that induction of PSA gene expression was dependent on AR was obtained from experiments using PC3 cells devoid of AR. Neither PSA, PB, nor ARR3 androgen-responsive reporters could be induced by activation of PKA in the absence of transfected AR. In addition, when nuclear AR from forskolin-treated LNCaP cells was incubated with oligonucleotides encoding an androgen response element of the PSA promoter and examined by electromobility shift assay, an increase in AR-androgen response element complex formation was observed. Lastly, cotransfection of an expression vector for a chimeric protein encoding the amino-terminal domain of the human AR linked to Gal4 and a 5xGal4UAS reporter gene construct resulted in activation of the amino-terminal domain of the AR by stimulation of PKA activity. These results demonstrate androgen-independent induction of PSA gene expression in prostate cancer cells by an AR-dependent pathway.  (+info)

Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency? (4/1203)

PURPOSE: The current investigators have shown that androgen treatment suppresses inflammation and stimulates the function of lacrimal glands in mouse models of Sjogren's syndrome. Recently, others have hypothesized that androgen insufficiency induces an autoimmune process in lacrimal tissue, leading to inflammation, a Sjogren's syndrome-like pathology, and aqueous tear deficiency. The purpose of the present study was to test this hypothesis. METHODS: Lacrimal glands were obtained from adult testicular feminized (Tfm) and control mice; castrated rats, guinea pigs, and rabbits; and castrated rats without anterior or whole pituitary glands and were processed for histology and image analysis. Tear volumes were measured in mice, in patients taking antiandrogen medications, and in age-matched human control subjects. RESULTS: Tfm mice, which are completely resistant to classical androgen action, did not have increased lymphocyte infiltration in their lacrimal glands or decreased tear volumes. No inflammation was evident in lacrimal tissues of male or female rats, guinea pigs, or rabbits 12 to 31 days after castration, no inflammation existed in rat lacrimal glands 15 to 31 days after orchiectomy and pituitary removal, and no aqueous tear deficiency was apparent in patients receiving antiandrogen therapy. CONCLUSIONS: Androgen deficiency may promote the progression of Sjogren's syndrome and its associated lacrimal gland inflammation, meibomian gland dysfunction, and severe dry eye. However, androgen insufficiency alone does not cause lacrimal gland inflammation, a Sjogren's syndrome-like pathology in lacrimal tissue, or aqueous tear deficiency in nonautoimmune animals and humans.  (+info)

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. (5/1203)

Overexpression of the HER2/Neu protooncogene has been linked to the progression of breast cancer. Here we demonstrate that the growth of prostate cancer LNCaP cells can also be increased by the stable transfection of HER2/Neu. Using AG879, a HER2/Neu inhibitor, and PD98059, a MAP kinase inhibitor, as well as MAP kinase phosphatase-1 (MPK-1), in the transfection assay, we found that HER2/Neu could induce prostate-specific antigen (PSA), a marker for the progression of prostate cancer, through the MAP kinase pathway at a low androgen level. Reporter assays and mammalian two-hybrid assays further suggest this HER2/Neu-induced androgen receptor (AR) transactivation may function through the promotion of interaction between AR and AR coactivators, such as ARA70. Furthermore, we found this HER2/Neu --> MAP kinase --> AR-ARAs --> PSA pathway could not be blocked completely by hydroxyflutamide, an antiandrogen used in the treatment of prostate cancer. Together, these data provide a novel pathway from HER2/Neu to AR transactivation, and they may represent one of the reasons for the PSA re-elevation and hormone resistance during androgen ablation therapy in prostate cancer patients.  (+info)

Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations. (6/1203)

Differential gene expression between the androgen sensitive human prostate cancer cell line LNCaP and an insensitive clonal variant, LNCaP-r, was demonstrated by suppression subtractive hybridization. Twenty-one sequences were identified of which 9 are homologous to known genes, 11 are represented by expressed sequence tags (ESTs), and 1 is novel. We present data for 5 of 7 sequences confirmed to be differentially expressed by Northern blot analysis and semiquantitative RT-PCR. Only one gene, fibronectin (FN), was highly overexpressed (>60-fold) in LNCaP-r cells, consistent with previously reported overexpression of FN in prostate cancer. Four sequences were down-regulated in LNCaP-r cells, including an inactive variant of the E2 ubiquitin conjugating enzyme (UEV-1), a novel metalloproteinase-related collagenase (PM5), and a potential tumor suppressor gene (breast basic conserved gene, BBC1). UEV-1 is multifunctional, regulates the cell cycle via cdk1, has homology to MMS2 and likewise functions as a DNA protection protein, and also has homology to TSG101. Aberrant splice variants of TSG101 occur frequently in both breast and prostate cancer, but its mechanism of action is unknown. FN, BBC1, and UEV-1 localize to regions of chromosomal aberration (2q3.4, 16q24.3, and 20q13.2, respectively) associated with advanced prostate cancer and thus may be highly relevant to disease progression.  (+info)

Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. (7/1203)

The INK4A gene maps to the 9p21 region and was initially described [M. Serrano et al., Nature (Lond.), 366: 704-707, 1993; A. Kamb et al., Science (Washington DC), 264: 436-440, 1994] as encoding a 148-amino-acid protein termed p16. The p16 protein associates exclusively with Cdk4 and Cdk6, inhibiting their complexation with D-type cyclins and the consequent phosphorylation of pRb. This contributes to cell cycle arrest. The purpose of the present study was to evaluate patterns of p16 expression in a well-characterized cohort of prostatic adenocarcinomas while exploring potential associations between alterations of p16 and clinicopathological variables. Normal and malignant tissues from 88 patients with prostate carcinoma were examined. In situ hybridization and immunohistochemistry assays were used to determine the status of the INK4A exon 1alpha transcripts and levels of p16 protein, respectively. Associations between altered patterns of expression and clinicopathological variables, including pretreatment prostate-specific antigen (PSA) level, Gleason grade, pathological stage, and hormonal status, were evaluated using the Mantel-Haenszel chi2 test. Biochemical (PSA) relapse after surgery was evaluated using the Kaplan-Meier method and the log-rank test. Levels of p16 expression and INK4A exon 1alpha transcripts in normal prostate and benign hyperplastic tissues were undetectable. However, p16 nuclear overexpression was observed in 38 (43%) prostate carcinomas, whereas the remaining 50 (57%) cases showed undetectable p16 levels. Overexpression of p16 protein was found to correlate with increased INK4A exon 1alpha transcripts. Moreover, p16 overexpression was associated with a higher pretreatment PSA level (P = 0.018), the use of neoadjuvant androgen ablation (P = 0.001), and a sooner time to PSA relapse after radical prostatectomy (P = 0.002). These data suggest that p16 overexpression is associated with tumor recurrence and a poor clinical course in patients with prostate cancer.  (+info)

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. (8/1203)

The role of androgen receptor (AR) mutations in androgen-independent prostate cancer (PCa) was determined by examining AR transcripts and genes from a large series of bone marrow metastases. Mutations were found in 5 of 16 patients who received combined androgen blockade with the AR antagonist flutamide, and these mutant ARs were strongly stimulated by flutamide. In contrast, the single mutant AR found among 17 patients treated with androgen ablation monotherapy was not flutamide stimulated. Patients with flutamide-stimulated AR mutations responded to subsequent treatment with bicalutamide, an AR antagonist that blocks the mutant ARs. These findings demonstrate that AR mutations occur in response to strong selective pressure from flutamide treatment.  (+info)

Androgen antagonists are a class of drugs that block the action of androgens, which are hormones that contribute to male sexual development and characteristics. They work by binding to androgen receptors in cells, preventing the natural androgens from attaching and exerting their effects. This can be useful in treating conditions that are caused or worsened by androgens, such as prostate cancer, hirsutism (excessive hair growth in women), and acne. Examples of androgen antagonists include flutamide, bicalutamide, and spironolactone.

Androgens are a class of hormones that are primarily responsible for the development and maintenance of male sexual characteristics and reproductive function. Testosterone is the most well-known androgen, but other androgens include dehydroepiandrosterone (DHEA), androstenedione, and dihydrotestosterone (DHT).

Androgens are produced primarily by the testes in men and the ovaries in women, although small amounts are also produced by the adrenal glands in both sexes. They play a critical role in the development of male secondary sexual characteristics during puberty, such as the growth of facial hair, deepening of the voice, and increased muscle mass.

In addition to their role in sexual development and function, androgens also have important effects on bone density, mood, and cognitive function. Abnormal levels of androgens can contribute to a variety of medical conditions, including infertility, erectile dysfunction, acne, hirsutism (excessive hair growth), and prostate cancer.

Flutamide is an anti-androgen medication, which is primarily used to treat prostate cancer. It works by blocking the action of androgens (male hormones), such as testosterone, on cancer cells. This helps to slow down or stop the growth of prostate cancer cells. Flutamide may be given in combination with other medications, such as a luteinizing hormone-releasing hormone (LHRH) agonist, to enhance its effectiveness. It is usually taken by mouth in the form of tablets.

Flutamide can have side effects, including breast tenderness and enlargement, hot flashes, nausea, vomiting, diarrhea, and loss of sexual desire. In rare cases, it may cause more serious side effects such as liver damage. It is important to be monitored by a healthcare professional while taking this medication to ensure that it is working properly and to manage any potential side effects.

Androgen receptors (ARs) are a type of nuclear receptor protein that are expressed in various tissues throughout the body. They play a critical role in the development and maintenance of male sexual characteristics and reproductive function. ARs are activated by binding to androgens, which are steroid hormones such as testosterone and dihydrotestosterone (DHT). Once activated, ARs function as transcription factors that regulate gene expression, ultimately leading to various cellular responses.

In the context of medical definitions, androgen receptors can be defined as follows:

Androgen receptors are a type of nuclear receptor protein that bind to androgens, such as testosterone and dihydrotestosterone, and mediate their effects on gene expression in various tissues. They play critical roles in the development and maintenance of male sexual characteristics and reproductive function, and are involved in the pathogenesis of several medical conditions, including prostate cancer, benign prostatic hyperplasia, and androgen deficiency syndromes.

Tosyl compounds are organic compounds that contain the tosyl group (p-toluenesulfonyl, -SO2C6H4CH3) as a substituent. The tosyl group is a protecting group or a good leaving group in organic reactions. Tosyl compounds are often prepared by reacting alcohols or amines with p-toluenesulfonyl chloride (TsCl) in the presence of a base.

The general formula for a tosyl compound can be represented as R-OTs, where R represents an organic group such as an alkyl, aryl, or heteroaryl group. Tosyl compounds are widely used in organic synthesis due to their versatility and reactivity.

Cyproterone acetate is a synthetic steroid hormone with anti-androgen and progestogenic properties. It works by blocking the action of androgens (male sex hormones) in the body, which helps to reduce symptoms associated with excessive androgen production such as severe acne or hirsutism (excessive hair growth).

Cyproterone acetate is used in the treatment of conditions such as prostate cancer, where it can help to slow the growth of cancer cells by reducing the levels of androgens in the body. It is also used in the treatment of sexual deviations, such as pedophilia or exhibitionism, as it can reduce sexual desire.

In addition, cyproterone acetate is sometimes used in combination with estrogen in hormone replacement therapy for transgender women to suppress the production of testosterone and promote feminization.

It's important to note that cyproterone acetate can have significant side effects and its use should be under the close supervision of a healthcare professional.

Dihydrotestosterone (DHT) is a sex hormone and androgen that plays a critical role in the development and maintenance of male characteristics, such as facial hair, deep voice, and muscle mass. It is synthesized from testosterone through the action of the enzyme 5-alpha reductase. DHT is essential for the normal development of the male genitalia during fetal development and for the maturation of the sexual organs at puberty.

In addition to its role in sexual development, DHT also contributes to the growth of hair follicles, the health of the prostate gland, and the maintenance of bone density. However, an excess of DHT has been linked to certain medical conditions, such as benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern baldness).

DHT exerts its effects by binding to androgen receptors in various tissues throughout the body. Once bound, DHT triggers a series of cellular responses that regulate gene expression and influence the growth and differentiation of cells. In some cases, these responses can lead to unwanted side effects, such as hair loss or prostate enlargement.

Medications that block the action of 5-alpha reductase, such as finasteride and dutasteride, are sometimes used to treat conditions associated with excess DHT production. These drugs work by reducing the amount of DHT available to bind to androgen receptors, thereby alleviating symptoms and slowing disease progression.

In summary, dihydrotestosterone is a potent sex hormone that plays a critical role in male sexual development and function. While it is essential for normal growth and development, an excess of DHT has been linked to certain medical conditions, such as BPH and androgenetic alopecia. Medications that block the action of 5-alpha reductase are sometimes used to treat these conditions by reducing the amount of DHT available to bind to androgen receptors.

Anilides are chemical compounds that result from the reaction between aniline (a organic compound with the formula C6H5NH2) and a carboxylic acid or its derivative. The resulting compound has the general structure R-CO-NH-C6H5, where R represents the rest of the carboxylic acid molecule.

Anilides are widely used in the pharmaceutical industry to produce various drugs, such as analgesics, anti-inflammatory agents, and antifungal agents. Some examples of anilide-based drugs include acetaminophen (also known as paracetamol), fenacetin, and flufenamic acid.

It's worth noting that some anilides have been found to have toxic effects on the liver and kidneys, so they must be used with caution and under medical supervision.

Prostatic neoplasms refer to abnormal growths in the prostate gland, which can be benign or malignant. The term "neoplasm" simply means new or abnormal tissue growth. When it comes to the prostate, neoplasms are often referred to as tumors.

Benign prostatic neoplasms, such as prostate adenomas, are non-cancerous overgrowths of prostate tissue. They usually grow slowly and do not spread to other parts of the body. While they can cause uncomfortable symptoms like difficulty urinating, they are generally not life-threatening.

Malignant prostatic neoplasms, on the other hand, are cancerous growths. The most common type of prostate cancer is adenocarcinoma, which arises from the glandular cells in the prostate. Prostate cancer often grows slowly and may not cause any symptoms for many years. However, some types of prostate cancer can be aggressive and spread quickly to other parts of the body, such as the bones or lymph nodes.

It's important to note that while prostate neoplasms can be concerning, early detection and treatment can significantly improve outcomes for many men. Regular check-ups with a healthcare provider are key to monitoring prostate health and catching any potential issues early on.

Androgen receptor antagonists are a class of drugs that block the action of androgens, which are hormones responsible for the development and maintenance of male sexual characteristics. These drugs work by binding to the androgen receptors in cells, preventing the natural androgens such as testosterone and dihydrotestosterone from binding and exerting their effects.

Androgen receptor antagonists are often used in the treatment of prostate cancer because androgens can stimulate the growth of prostate cancer cells. By blocking the action of androgens, these drugs can help to slow or stop the growth of prostate cancer tumors. Some examples of androgen receptor antagonists include flutamide, bicalutamide, and enzalutamide.

It's important to note that androgen receptor antagonists can have side effects, including hot flashes, breast tenderness or enlargement, decreased sex drive, and impotence. Additionally, long-term use of these drugs can lead to muscle loss, bone density loss, and an increased risk of fractures. As with any medication, it's important to discuss the potential benefits and risks with a healthcare provider before starting treatment.

Testosterone is a steroid hormone that belongs to androsten class of hormones. It is primarily secreted by the Leydig cells in the testes of males and, to a lesser extent, by the ovaries and adrenal glands in females. Testosterone is the main male sex hormone and anabolic steroid. It plays a key role in the development of masculine characteristics, such as body hair and muscle mass, and contributes to bone density, fat distribution, red cell production, and sex drive. In females, testosterone contributes to sexual desire and bone health. Testosterone is synthesized from cholesterol and its production is regulated by luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Testosterone congeners refer to structural analogs or derivatives of testosterone, which is the primary male sex hormone and an androgen. These are compounds that have a similar chemical structure to testosterone and may exhibit similar biological activities. Testosterone congeners can be naturally occurring or synthetic and include a variety of compounds such as androgens, anabolic steroids, and estrogens. They can be used in medical treatments, but some are also misused for performance enhancement or other non-medical purposes, which can lead to various health risks and side effects.

Metribolone is a synthetic anabolic-androgenic steroid (AAS) drug, which is not widely used in clinical medicine. Its chemical structure and pharmacological properties are similar to the natural male hormone testosterone. It has been used in research settings to study its effects on muscle growth, bone density, and sexual development. However, due to its potential for abuse and serious side effects, it is not approved for use in many countries.

It's important to note that the possession, distribution, and use of anabolic steroids without a valid prescription is illegal and can be dangerous to one's health. It can cause a range of adverse effects such as liver damage, cardiovascular disease, hormonal imbalances, and psychological issues among others.

Hormone antagonists are substances or drugs that block the action of hormones by binding to their receptors without activating them, thereby preventing the hormones from exerting their effects. They can be classified into two types: receptor antagonists and enzyme inhibitors. Receptor antagonists bind directly to hormone receptors and prevent the hormone from binding, while enzyme inhibitors block the production or breakdown of hormones by inhibiting specific enzymes involved in their metabolism. Hormone antagonists are used in the treatment of various medical conditions, such as cancer, hormonal disorders, and cardiovascular diseases.

Androgen Insensitivity Syndrome (AIS) is a genetic condition that occurs in individuals who are genetically male (have one X and one Y chromosome) but are resistant to androgens, which are hormones that play a role in male sexual development. This resistance is caused by changes (mutations) in the gene for the androgen receptor.

There are three main types of AIS: complete androgen insensitivity syndrome (CAIS), partial androgen insensitivity syndrome (PAIS), and mild androgen insensitivity syndrome (MAIS).

In CAIS, individuals are completely resistant to androgens, which results in the development of female external genitalia at birth. Despite having testes, these individuals do not have a functioning male reproductive system and typically have a female gender identity. They may be diagnosed during adolescence when they do not begin to menstruate or experience other signs of puberty.

In PAIS and MAIS, the degree of androgen insensitivity varies, resulting in a range of physical characteristics that can include both male and female features. These individuals may have ambiguous genitalia at birth, and their gender identity may not align with their genetic sex.

It's important to note that people with AIS are typically healthy and do not have an increased risk of medical conditions beyond those related to their hormonal differences. However, they may face challenges related to their gender identity, sexual development, and fertility. It is recommended that individuals with AIS receive comprehensive medical care and support from a team of healthcare professionals who specialize in this condition.

Dopamine antagonists are a class of drugs that block the action of dopamine, a neurotransmitter in the brain associated with various functions including movement, motivation, and emotion. These drugs work by binding to dopamine receptors and preventing dopamine from attaching to them, which can help to reduce the symptoms of certain medical conditions such as schizophrenia, bipolar disorder, and gastroesophageal reflux disease (GERD).

There are several types of dopamine antagonists, including:

1. Typical antipsychotics: These drugs are primarily used to treat psychosis, including schizophrenia and delusional disorders. Examples include haloperidol, chlorpromazine, and fluphenazine.
2. Atypical antipsychotics: These drugs are also used to treat psychosis but have fewer side effects than typical antipsychotics. They may also be used to treat bipolar disorder and depression. Examples include risperidone, olanzapine, and quetiapine.
3. Antiemetics: These drugs are used to treat nausea and vomiting. Examples include metoclopramide and prochlorperazine.
4. Dopamine agonists: While not technically dopamine antagonists, these drugs work by stimulating dopamine receptors and can be used to treat conditions such as Parkinson's disease. However, they can also have the opposite effect and block dopamine receptors in high doses, making them functionally similar to dopamine antagonists.

Common side effects of dopamine antagonists include sedation, weight gain, and movement disorders such as tardive dyskinesia. It's important to use these drugs under the close supervision of a healthcare provider to monitor for side effects and adjust the dosage as needed.

Excitatory amino acid antagonists are a class of drugs that block the action of excitatory neurotransmitters, particularly glutamate and aspartate, in the brain. These drugs work by binding to and blocking the receptors for these neurotransmitters, thereby reducing their ability to stimulate neurons and produce an excitatory response.

Excitatory amino acid antagonists have been studied for their potential therapeutic benefits in a variety of neurological conditions, including stroke, epilepsy, traumatic brain injury, and neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. However, their use is limited by the fact that blocking excitatory neurotransmission can also have negative effects on cognitive function and memory.

There are several types of excitatory amino acid receptors, including N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainite receptors. Different excitatory amino acid antagonists may target one or more of these receptor subtypes, depending on their specific mechanism of action.

Examples of excitatory amino acid antagonists include ketamine, memantine, and dextromethorphan. These drugs have been used in clinical practice for various indications, such as anesthesia, sedation, and treatment of neurological disorders. However, their use must be carefully monitored due to potential side effects and risks associated with blocking excitatory neurotransmission.

Neurokinin-1 (NK-1) receptor antagonists are a class of drugs that block the action of substance P, a neuropeptide involved in pain transmission and inflammation. These drugs work by binding to NK-1 receptors found on nerve cells, preventing substance P from activating them and transmitting pain signals. NK-1 receptor antagonists have been studied for their potential use in treating various conditions associated with pain and inflammation, such as migraine headaches, depression, and irritable bowel syndrome. Some examples of NK-1 receptor antagonists include aprepitant, fosaprepitant, and rolapitant.

Narcotic antagonists are a class of medications that block the effects of opioids, a type of narcotic pain reliever, by binding to opioid receptors in the brain and blocking the activation of these receptors by opioids. This results in the prevention or reversal of opioid-induced effects such as respiratory depression, sedation, and euphoria. Narcotic antagonists are used for a variety of medical purposes, including the treatment of opioid overdose, the management of opioid dependence, and the prevention of opioid-induced side effects in certain clinical situations. Examples of narcotic antagonists include naloxone, naltrexone, and methylnaltrexone.

Histamine H2 antagonists, also known as H2 blockers, are a class of medications that work by blocking the action of histamine on the H2 receptors in the stomach. Histamine is a chemical that is released by the body during an allergic reaction and can also be released by certain cells in the stomach in response to food or other stimuli. When histamine binds to the H2 receptors in the stomach, it triggers the release of acid. By blocking the action of histamine on these receptors, H2 antagonists reduce the amount of acid produced by the stomach, which can help to relieve symptoms such as heartburn, indigestion, and stomach ulcers. Examples of H2 antagonists include ranitidine (Zantac), famotidine (Pepcid), and cimetidine (Tagamet).

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

The prostate is a small gland that is part of the male reproductive system. Its main function is to produce a fluid that, together with sperm cells from the testicles and fluids from other glands, makes up semen. This fluid nourishes and protects the sperm, helping it to survive and facilitating its movement.

The prostate is located below the bladder and in front of the rectum. It surrounds part of the urethra, the tube that carries urine and semen out of the body. This means that prostate problems can affect urination and sexual function. The prostate gland is about the size of a walnut in adult men.

Prostate health is an important aspect of male health, particularly as men age. Common prostate issues include benign prostatic hyperplasia (BPH), which is an enlarged prostate not caused by cancer, and prostate cancer, which is one of the most common types of cancer in men. Regular check-ups with a healthcare provider can help to detect any potential problems early and improve outcomes.

Interleukin-1 Receptor Antagonist Protein (IL-1Ra) is a naturally occurring protein that acts as a competitive inhibitor of the interleukin-1 (IL-1) receptor. IL-1 is a pro-inflammatory cytokine involved in various physiological processes, including the immune response and inflammation. The binding of IL-1 to its receptor triggers a signaling cascade that leads to the activation of inflammatory genes and cellular responses.

IL-1Ra shares structural similarities with IL-1 but does not initiate the downstream signaling pathway. Instead, it binds to the same receptor site as IL-1, preventing IL-1 from interacting with its receptor and thus inhibiting the inflammatory response.

Increased levels of IL-1Ra have been found in various inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease, and sepsis, where it acts to counterbalance the pro-inflammatory effects of IL-1. Recombinant IL-1Ra (Anakinra) is used clinically as a therapeutic agent for the treatment of rheumatoid arthritis and other inflammatory diseases.

Sprague-Dawley rats are a strain of albino laboratory rats that are widely used in scientific research. They were first developed by researchers H.H. Sprague and R.C. Dawley in the early 20th century, and have since become one of the most commonly used rat strains in biomedical research due to their relatively large size, ease of handling, and consistent genetic background.

Sprague-Dawley rats are outbred, which means that they are genetically diverse and do not suffer from the same limitations as inbred strains, which can have reduced fertility and increased susceptibility to certain diseases. They are also characterized by their docile nature and low levels of aggression, making them easier to handle and study than some other rat strains.

These rats are used in a wide variety of research areas, including toxicology, pharmacology, nutrition, cancer, and behavioral studies. Because they are genetically diverse, Sprague-Dawley rats can be used to model a range of human diseases and conditions, making them an important tool in the development of new drugs and therapies.

Muscarinic antagonists, also known as muscarinic receptor antagonists or parasympatholytics, are a class of drugs that block the action of acetylcholine at muscarinic receptors. Acetylcholine is a neurotransmitter that plays an important role in the parasympathetic nervous system, which helps to regulate various bodily functions such as heart rate, digestion, and respiration.

Muscarinic antagonists work by binding to muscarinic receptors, which are found in various organs throughout the body, including the eyes, lungs, heart, and gastrointestinal tract. By blocking the action of acetylcholine at these receptors, muscarinic antagonists can produce a range of effects depending on the specific receptor subtype that is affected.

For example, muscarinic antagonists may be used to treat conditions such as chronic obstructive pulmonary disease (COPD) and asthma by relaxing the smooth muscle in the airways and reducing bronchoconstriction. They may also be used to treat conditions such as urinary incontinence or overactive bladder by reducing bladder contractions.

Some common muscarinic antagonists include atropine, scopolamine, ipratropium, and tiotropium. It's important to note that these drugs can have significant side effects, including dry mouth, blurred vision, constipation, and confusion, especially when used in high doses or for prolonged periods of time.

GABA (gamma-aminobutyric acid) antagonists are substances that block the action of GABA, which is the primary inhibitory neurotransmitter in the central nervous system. GABA plays a crucial role in regulating neuronal excitability and reducing the transmission of nerve impulses.

GABA antagonists work by binding to the GABA receptors without activating them, thereby preventing the normal function of GABA and increasing neuronal activity. These agents can cause excitation of the nervous system, leading to various effects depending on the specific type of GABA receptor they target.

GABA antagonists are used in medical treatments for certain conditions, such as sleep disorders, depression, and cognitive enhancement. However, they can also have adverse effects, including anxiety, agitation, seizures, and even neurotoxicity at high doses. Examples of GABA antagonists include picrotoxin, bicuculline, and flumazenil.

Histamine H1 antagonists, also known as H1 blockers or antihistamines, are a class of medications that work by blocking the action of histamine at the H1 receptor. Histamine is a chemical mediator released by mast cells and basophils in response to an allergic reaction or injury. It causes various symptoms such as itching, sneezing, runny nose, and wheal and flare reactions (hives).

H1 antagonists prevent the binding of histamine to its receptor, thereby alleviating these symptoms. They are commonly used to treat allergic conditions such as hay fever, hives, and eczema, as well as motion sickness and insomnia. Examples of H1 antagonists include diphenhydramine (Benadryl), loratadine (Claritin), cetirizine (Zyrtec), and doxylamine (Unisom).

Piperidines are not a medical term per se, but they are a class of organic compounds that have important applications in the pharmaceutical industry. Medically relevant piperidines include various drugs such as some antihistamines, antidepressants, and muscle relaxants.

A piperidine is a heterocyclic amine with a six-membered ring containing five carbon atoms and one nitrogen atom. The structure can be described as a cyclic secondary amine. Piperidines are found in some natural alkaloids, such as those derived from the pepper plant (Piper nigrum), which gives piperidines their name.

In a medical context, it is more common to encounter specific drugs that belong to the class of piperidines rather than the term itself.

Purinergic P1 receptor antagonists are a class of pharmaceutical drugs that block the activity of purinergic P1 receptors, which are a type of G-protein coupled receptor found in many tissues throughout the body. These receptors are activated by extracellular nucleotides such as adenosine and ATP, and play important roles in regulating a variety of physiological processes, including cardiovascular function, neurotransmission, and immune response.

Purinergic P1 receptor antagonists work by binding to these receptors and preventing them from being activated by nucleotides. This can have various therapeutic effects, depending on the specific receptor subtype that is targeted. For example, A1 receptor antagonists have been shown to improve cardiac function in heart failure, while A2A receptor antagonists have potential as anti-inflammatory and neuroprotective agents.

However, it's important to note that the use of purinergic P1 receptor antagonists is still an area of active research, and more studies are needed to fully understand their mechanisms of action and therapeutic potential.

Androstenedione is a steroid hormone produced by the adrenal glands, ovaries, and testes. It is a precursor to both male and female sex hormones, including testosterone and estrogen. In the adrenal glands, it is produced from cholesterol through a series of biochemical reactions involving several enzymes. Androstenedione can also be converted into other steroid hormones, such as dehydroepiandrosterone (DHEA) and estrone.

In the body, androstenedione plays an important role in the development and maintenance of secondary sexual characteristics, such as facial hair and a deep voice in men, and breast development and menstrual cycles in women. It also contributes to bone density, muscle mass, and overall physical strength.

Androstenedione is available as a dietary supplement and has been marketed as a way to boost athletic performance and increase muscle mass. However, its effectiveness for these purposes is not supported by scientific evidence, and it may have harmful side effects when taken in high doses or for extended periods of time. Additionally, the use of androstenedione as a dietary supplement is banned by many sports organizations, including the International Olympic Committee and the National Collegiate Athletic Association.

Histamine antagonists, also known as histamine blockers or H1-blockers, are a class of medications that work by blocking the action of histamine, a substance in the body that is released during an allergic reaction. Histamine causes many of the symptoms of an allergic response, such as itching, sneezing, runny nose, and hives. By blocking the effects of histamine, these medications can help to relieve or prevent allergy symptoms.

Histamine antagonists are often used to treat conditions such as hay fever, hives, and other allergic reactions. They may also be used to treat stomach ulcers caused by excessive production of stomach acid. Some examples of histamine antagonists include diphenhydramine (Benadryl), loratadine (Claritin), and famotidine (Pepcid).

It's important to note that while histamine antagonists can be effective at relieving allergy symptoms, they do not cure allergies or prevent the release of histamine. They simply block its effects. It's also worth noting that these medications can have side effects, such as drowsiness, dry mouth, and dizziness, so it's important to follow your healthcare provider's instructions carefully when taking them.

Nicotinic antagonists are a class of drugs that block the action of nicotine at nicotinic acetylcholine receptors (nAChRs). These receptors are found in the nervous system and are activated by the neurotransmitter acetylcholine, as well as by nicotine. When nicotine binds to these receptors, it can cause the release of various neurotransmitters, including dopamine, which can lead to rewarding effects and addiction.

Nicotinic antagonists work by binding to nAChRs and preventing nicotine from activating them. This can help to reduce the rewarding effects of nicotine and may be useful in treating nicotine addiction. Examples of nicotinic antagonists include mecamylamine, varenicline, and cytisine.

It's important to note that while nicotinic antagonists can help with nicotine addiction, they can also have side effects, such as nausea, vomiting, and abnormal dreams. Additionally, some people may experience more serious side effects, such as seizures or cardiovascular problems, so it's important to use these medications under the close supervision of a healthcare provider.

Hormone-dependent neoplasms are a type of tumor that requires the presence of specific hormones to grow and multiply. These neoplasms have receptors on their cell surfaces that bind to the hormones, leading to the activation of signaling pathways that promote cell division and growth.

Examples of hormone-dependent neoplasms include breast cancer, prostate cancer, and endometrial cancer. In breast cancer, for instance, estrogen and/or progesterone can bind to their respective receptors on the surface of cancer cells, leading to the activation of signaling pathways that promote tumor growth. Similarly, in prostate cancer, androgens such as testosterone can bind to androgen receptors on the surface of cancer cells, promoting cell division and tumor growth.

Hormone-dependent neoplasms are often treated with hormonal therapies that aim to reduce or block the production of the relevant hormones or interfere with their ability to bind to their respective receptors. This can help slow down or stop the growth of the tumor and improve outcomes for patients.

Adenosine A2 receptor antagonists are a class of pharmaceutical compounds that block the action of adenosine at A2 receptors. Adenosine is a naturally occurring molecule in the body that acts as a neurotransmitter and has various physiological effects, including vasodilation and inhibition of heart rate.

Adenosine A2 receptor antagonists work by binding to A2 receptors and preventing adenosine from activating them. This results in the opposite effect of adenosine, leading to vasoconstriction and increased heart rate. These drugs are used for a variety of medical conditions, including asthma, chronic obstructive pulmonary disease (COPD), and heart failure.

Examples of Adenosine A2 receptor antagonists include theophylline, caffeine, and some newer drugs such asistradefylline and tozadenant. These drugs have different pharmacological properties and are used for specific medical conditions. It is important to note that adenosine A2 receptor antagonists can have side effects, including restlessness, insomnia, and gastrointestinal symptoms, and should be used under the guidance of a healthcare professional.

Adrenergic alpha-1 receptor antagonists, also known as alpha-blockers, are a class of medications that block the effects of the neurotransmitter norepinephrine at alpha-1 receptors. These receptors are found in various tissues throughout the body, including the smooth muscle of blood vessels, the bladder, and the eye.

When norepinephrine binds to alpha-1 receptors, it causes smooth muscle to contract, leading to vasoconstriction (constriction of blood vessels), increased blood pressure, and other effects. By blocking these receptors, alpha-blockers can cause relaxation of smooth muscle, leading to vasodilation (expansion of blood vessels), decreased blood pressure, and other effects.

Alpha-blockers are used in the treatment of various medical conditions, including hypertension (high blood pressure), benign prostatic hyperplasia (enlarged prostate), and pheochromocytoma (a rare tumor of the adrenal gland). Examples of alpha-blockers include doxazosin, prazosin, and terazosin.

It's important to note that while alpha-blockers can be effective in treating certain medical conditions, they can also have side effects, such as dizziness, lightheadedness, and orthostatic hypotension (a sudden drop in blood pressure when standing up). As with any medication, it's important to use alpha-blockers under the guidance of a healthcare provider.

Purinergic P2 receptor antagonists are pharmaceutical agents that block the activity of P2 receptors, which are a type of cell surface receptor that binds extracellular nucleotides such as ATP and ADP. These receptors play important roles in various physiological processes, including neurotransmission, inflammation, and platelet aggregation.

P2 receptors are divided into two main subfamilies: P2X and P2Y. The P2X receptors are ligand-gated ion channels that allow the flow of ions across the cell membrane upon activation, while the P2Y receptors are G protein-coupled receptors that activate intracellular signaling pathways.

Purinergic P2 receptor antagonists are used in clinical medicine to treat various conditions, such as chronic pain, urinary incontinence, and cardiovascular diseases. For example, the P2X3 receptor antagonist gefapixant is being investigated for the treatment of refractory chronic cough, while the P2Y12 receptor antagonists clopidogrel and ticagrelor are used to prevent thrombosis in patients with acute coronary syndrome.

Overall, purinergic P2 receptor antagonists offer a promising therapeutic approach for various diseases by targeting specific receptors involved in pathological processes.

Nandrolone is a synthetic anabolic-androgenic steroid, which is a type of hormone that is similar to testosterone. It is often used in medical settings for the treatment of certain conditions such as muscle wasting diseases, osteoporosis, and breast cancer in women. Nandrolone promotes muscle growth and increases appetite, which can help individuals with muscle wasting diseases or other conditions that cause muscle loss to maintain their strength and weight.

Nandrolone is also known by its brand names Deca-Durabolin and Durabolin. It works by increasing the production of proteins in the body, which helps to build muscle mass. Nandrolone can have both anabolic (muscle-building) and androgenic (masculinizing) effects, although it is generally considered to be less androgenic than testosterone.

Like other anabolic steroids, nandrolone can have a number of side effects, including acne, hair loss, liver damage, and mood changes. It can also cause virilization in women, which refers to the development of male characteristics such as a deep voice, facial hair, and a decrease in breast size. Nandrolone is classified as a controlled substance in many countries due to its potential for abuse and dependence.

Androstane-3,17-diol is a steroid hormone, specifically a 17-ketosteroid, that is synthesized from the metabolism of androgens such as testosterone. It exists in two forms: 5α-androstane-3α,17β-diol and 5β-androstane-3α,17β-diol, which differ based on the configuration of the A ring at the 5 position. These compounds are weak androgens themselves but serve as important intermediates in steroid hormone metabolism. They can be further metabolized to form other steroid hormones or their metabolites, such as androstanediol glucuronide, which is a major urinary metabolite of testosterone and dihydrotestosterone.

Dehydroepiandrosterone (DHEA) is a steroid hormone produced by the adrenal glands. It serves as a precursor to other hormones, including androgens such as testosterone and estrogens such as estradiol. DHEA levels typically peak during early adulthood and then gradually decline with age.

DHEA has been studied for its potential effects on various health conditions, including aging, cognitive function, sexual dysfunction, and certain chronic diseases. However, the evidence supporting its use for these purposes is generally limited and inconclusive. As with any supplement or medication, it's important to consult with a healthcare provider before taking DHEA to ensure safety and effectiveness.

Serotonin 5-HT3 receptor antagonists are a class of medications that work by blocking the serotonin 5-HT3 receptors, which are found in the gastrointestinal tract and the brain. These receptors play a role in regulating nausea and vomiting, among other functions.

When serotonin binds to these receptors, it can trigger a series of events that lead to nausea and vomiting, particularly in response to chemotherapy or surgery. By blocking the 5-HT3 receptors, serotonin cannot bind to them and therefore cannot trigger these events, which helps to reduce nausea and vomiting.

Examples of 5-HT3 receptor antagonists include ondansetron (Zofran), granisetron (Kytril), palonosetron (Aloxi), and dolasetron (Anzemet). These medications are commonly used to prevent and treat nausea and vomiting associated with chemotherapy, radiation therapy, and surgery.

Serotonin 5-HT2 receptor antagonists are a class of drugs that block the action of serotonin, a neurotransmitter, at 5-HT2 receptors. These receptors are found in the central and peripheral nervous systems and are involved in various physiological functions such as mood regulation, cognition, appetite control, and vasoconstriction.

By blocking the action of serotonin at these receptors, serotonin 5-HT2 receptor antagonists can produce a range of effects depending on the specific receptor subtype that they target. For example, some serotonin 5-HT2 receptor antagonists are used to treat psychiatric disorders such as schizophrenia and depression, while others are used to treat migraines or prevent nausea and vomiting associated with chemotherapy.

Some common examples of serotonin 5-HT2 receptor antagonists include risperidone, olanzapine, and paliperidone (used for the treatment of schizophrenia), mirtazapine (used for the treatment of depression), sumatriptan (used for the treatment of migraines), and ondansetron (used to prevent nausea and vomiting).

3-Oxo-5-alpha-steroid 4-dehydrogenase is an enzyme that plays a role in steroid metabolism. It is involved in the conversion of certain steroids into others by removing hydrogen atoms and adding oxygen to create double bonds in the steroid molecule. Specifically, this enzyme catalyzes the dehydrogenation of 3-oxo-5-alpha-steroids at the 4th position, which results in the formation of a 4,5-double bond.

The enzyme is found in various tissues throughout the body and is involved in the metabolism of several important steroid hormones, including cortisol, aldosterone, and androgens. It helps to regulate the levels of these hormones in the body by converting them into their active or inactive forms as needed.

Deficiencies or mutations in the 3-oxo-5-alpha-steroid 4-dehydrogenase enzyme can lead to various medical conditions, such as congenital adrenal hyperplasia, which is characterized by abnormal hormone levels and development of sexual characteristics.

"Wistar rats" are a strain of albino rats that are widely used in laboratory research. They were developed at the Wistar Institute in Philadelphia, USA, and were first introduced in 1906. Wistar rats are outbred, which means that they are genetically diverse and do not have a fixed set of genetic characteristics like inbred strains.

Wistar rats are commonly used as animal models in biomedical research because of their size, ease of handling, and relatively low cost. They are used in a wide range of research areas, including toxicology, pharmacology, nutrition, cancer, cardiovascular disease, and behavioral studies. Wistar rats are also used in safety testing of drugs, medical devices, and other products.

Wistar rats are typically larger than many other rat strains, with males weighing between 500-700 grams and females weighing between 250-350 grams. They have a lifespan of approximately 2-3 years. Wistar rats are also known for their docile and friendly nature, making them easy to handle and work with in the laboratory setting.

A cell line that is derived from tumor cells and has been adapted to grow in culture. These cell lines are often used in research to study the characteristics of cancer cells, including their growth patterns, genetic changes, and responses to various treatments. They can be established from many different types of tumors, such as carcinomas, sarcomas, and leukemias. Once established, these cell lines can be grown and maintained indefinitely in the laboratory, allowing researchers to conduct experiments and studies that would not be feasible using primary tumor cells. It is important to note that tumor cell lines may not always accurately represent the behavior of the original tumor, as they can undergo genetic changes during their time in culture.

Adenosine A1 receptor antagonists are a class of pharmaceutical compounds that block the action of adenosine at A1 receptors. Adenosine is a naturally occurring purine nucleoside that acts as a neurotransmitter and modulator of various physiological processes, including cardiovascular function, neuronal excitability, and immune response.

Adenosine exerts its effects by binding to specific receptors on the surface of cells, including A1, A2A, A2B, and A3 receptors. The activation of A1 receptors leads to a variety of physiological responses, such as vasodilation, negative chronotropy (slowing of heart rate), and negative inotropy (reduced contractility) of the heart, as well as inhibition of neurotransmitter release in the brain.

Adenosine A1 receptor antagonists work by binding to and blocking the action of adenosine at A1 receptors, thereby preventing or reducing its effects on these physiological processes. These drugs have been investigated for their potential therapeutic uses in various conditions, such as heart failure, cardiac arrest, and neurological disorders.

Examples of adenosine A1 receptor antagonists include:

* Dipyridamole: a vasodilator used to treat peripheral arterial disease and to prevent blood clots.
* Caffeine: a natural stimulant found in coffee, tea, and chocolate, which acts as a weak A1 receptor antagonist.
* Rolofylline: an experimental drug that has been investigated for its potential use in treating acute ischemic stroke and traumatic brain injury.
* KW-3902: another experimental drug that has been studied for its potential therapeutic effects in heart failure, cardiac arrest, and neurodegenerative disorders.

It's important to note that adenosine A1 receptor antagonists may have side effects and potential risks, and their use should be monitored and managed by healthcare professionals.

Leukotriene antagonists are a class of medications that work by blocking the action of leukotrienes, which are chemicals released by the immune system in response to an allergen or irritant. Leukotrienes cause airway muscles to tighten and inflammation in the airways, leading to symptoms such as wheezing, shortness of breath, and coughing. By blocking the action of leukotrienes, leukotriene antagonists can help relieve these symptoms and improve lung function. These medications are often used to treat asthma and allergic rhinitis (hay fever). Examples of leukotriene antagonists include montelukast, zafirlukast, and pranlukast.

Angiotensin receptor antagonists (ARAs), also known as angiotensin II receptor blockers (ARBs), are a class of medications used to treat hypertension, heart failure, and protect against kidney damage in patients with diabetes. They work by blocking the action of angiotensin II, a potent vasoconstrictor and hormone that increases blood pressure and promotes tissue fibrosis. By blocking the binding of angiotensin II to its receptors, ARAs cause relaxation of blood vessels, decreased sodium and water retention, and reduced cardiac remodeling, ultimately leading to improved cardiovascular function and reduced risk of organ damage. Examples of ARAs include losartan, valsartan, irbesartan, and candesartan.

Estradiol is a type of estrogen, which is a female sex hormone. It is the most potent and dominant form of estrogen in humans. Estradiol plays a crucial role in the development and maintenance of secondary sexual characteristics in women, such as breast development and regulation of the menstrual cycle. It also helps maintain bone density, protect the lining of the uterus, and is involved in cognition and mood regulation.

Estradiol is produced primarily by the ovaries, but it can also be synthesized in smaller amounts by the adrenal glands and fat cells. In men, estradiol is produced from testosterone through a process called aromatization. Abnormal levels of estradiol can contribute to various health issues, such as hormonal imbalances, infertility, osteoporosis, and certain types of cancer.

Signal transduction is the process by which a cell converts an extracellular signal, such as a hormone or neurotransmitter, into an intracellular response. This involves a series of molecular events that transmit the signal from the cell surface to the interior of the cell, ultimately resulting in changes in gene expression, protein activity, or metabolism.

The process typically begins with the binding of the extracellular signal to a receptor located on the cell membrane. This binding event activates the receptor, which then triggers a cascade of intracellular signaling molecules, such as second messengers, protein kinases, and ion channels. These molecules amplify and propagate the signal, ultimately leading to the activation or inhibition of specific cellular responses.

Signal transduction pathways are highly regulated and can be modulated by various factors, including other signaling molecules, post-translational modifications, and feedback mechanisms. Dysregulation of these pathways has been implicated in a variety of diseases, including cancer, diabetes, and neurological disorders.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

"Competitive binding" is a term used in pharmacology and biochemistry to describe the behavior of two or more molecules (ligands) competing for the same binding site on a target protein or receptor. In this context, "binding" refers to the physical interaction between a ligand and its target.

When a ligand binds to a receptor, it can alter the receptor's function, either activating or inhibiting it. If multiple ligands compete for the same binding site, they will compete to bind to the receptor. The ability of each ligand to bind to the receptor is influenced by its affinity for the receptor, which is a measure of how strongly and specifically the ligand binds to the receptor.

In competitive binding, if one ligand is present in high concentrations, it can prevent other ligands with lower affinity from binding to the receptor. This is because the higher-affinity ligand will have a greater probability of occupying the binding site and blocking access to the other ligands. The competition between ligands can be described mathematically using equations such as the Langmuir isotherm, which describes the relationship between the concentration of ligand and the fraction of receptors that are occupied by the ligand.

Competitive binding is an important concept in drug development, as it can be used to predict how different drugs will interact with their targets and how they may affect each other's activity. By understanding the competitive binding properties of a drug, researchers can optimize its dosage and delivery to maximize its therapeutic effect while minimizing unwanted side effects.

Adrenergic alpha-2 receptor antagonists are a class of medications that block the action of norepinephrine, a neurotransmitter and hormone, at adrenergic alpha-2 receptors. These receptors are found in the central and peripheral nervous system and play a role in regulating various physiological functions such as blood pressure, heart rate, and insulin secretion.

By blocking the action of norepinephrine at these receptors, adrenergic alpha-2 receptor antagonists can increase sympathetic nervous system activity, leading to vasodilation, increased heart rate, and increased insulin secretion. These effects make them useful in the treatment of conditions such as hypotension (low blood pressure), opioid-induced sedation and respiratory depression, and diagnostic procedures that require vasodilation.

Examples of adrenergic alpha-2 receptor antagonists include yohimbine, idazoxan, and atipamezole. It's important to note that these medications can have significant side effects, including hypertension, tachycardia, and agitation, and should be used under the close supervision of a healthcare provider.

Gonadotropin-Releasing Hormone (GnRH), also known as Luteinizing Hormone-Releasing Hormone (LHRH), is a hormonal peptide consisting of 10 amino acids. It is produced and released by the hypothalamus, an area in the brain that links the nervous system to the endocrine system via the pituitary gland.

GnRH plays a crucial role in regulating reproduction and sexual development through its control of two gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These gonadotropins, in turn, stimulate the gonads (ovaries or testes) to produce sex steroids and eggs or sperm.

GnRH acts on the anterior pituitary gland by binding to its specific receptors, leading to the release of FSH and LH. The hypothalamic-pituitary-gonadal axis is under negative feedback control, meaning that when sex steroid levels are high, they inhibit the release of GnRH, which subsequently decreases FSH and LH secretion.

GnRH agonists and antagonists have clinical applications in various medical conditions, such as infertility treatments, precocious puberty, endometriosis, uterine fibroids, prostate cancer, and hormone-responsive breast cancer.

Adrenergic antagonists, also known as beta blockers or sympatholytic drugs, are a class of medications that block the effects of adrenaline and noradrenaline (also known as epinephrine and norepinephrine) on the body. These neurotransmitters are part of the sympathetic nervous system and play a role in the "fight or flight" response, increasing heart rate, blood pressure, and respiratory rate.

Adrenergic antagonists work by binding to beta-adrenergic receptors in the body, preventing the neurotransmitters from activating them. This results in a decrease in heart rate, blood pressure, and respiratory rate. These medications are used to treat various conditions such as hypertension, angina, heart failure, arrhythmias, glaucoma, and anxiety disorders.

There are two types of adrenergic antagonists: beta blockers and alpha blockers. Beta blockers selectively bind to beta-adrenergic receptors, while alpha blockers bind to alpha-adrenergic receptors. Some medications, such as labetalol, have both beta and alpha blocking properties.

It is important to note that adrenergic antagonists can interact with other medications and may cause side effects, so it is essential to use them under the guidance of a healthcare professional.

GABA-A receptor antagonists are pharmacological agents that block the action of gamma-aminobutyric acid (GABA) at GABA-A receptors. GABA is the primary inhibitory neurotransmitter in the central nervous system, and it exerts its effects by binding to GABA-A receptors, which are ligand-gated chloride channels. When GABA binds to these receptors, it opens the chloride channel, leading to an influx of chloride ions into the neuron and hyperpolarization of the membrane, making it less likely to fire.

GABA-A receptor antagonists work by binding to the GABA-A receptor and preventing GABA from binding, thereby blocking the inhibitory effects of GABA. This can lead to increased neuronal excitability and can result in a variety of effects depending on the specific antagonist and the location of the receptors involved.

GABA-A receptor antagonists have been used in research to study the role of GABA in various physiological processes, and some have been investigated as potential therapeutic agents for conditions such as anxiety, depression, and insomnia. However, their use is limited by their potential to cause seizures and other adverse effects due to excessive neuronal excitation. Examples of GABA-A receptor antagonists include picrotoxin, bicuculline, and flumazenil.

Nitriles, in a medical context, refer to a class of organic compounds that contain a cyano group (-CN) bonded to a carbon atom. They are widely used in the chemical industry and can be found in various materials, including certain plastics and rubber products.

In some cases, nitriles can pose health risks if ingested, inhaled, or come into contact with the skin. Short-term exposure to high levels of nitriles can cause irritation to the eyes, nose, throat, and respiratory tract. Prolonged or repeated exposure may lead to more severe health effects, such as damage to the nervous system, liver, and kidneys.

However, it's worth noting that the medical use of nitriles is not very common. Some nitrile gloves are used in healthcare settings due to their resistance to many chemicals and because they can provide a better barrier against infectious materials compared to latex or vinyl gloves. But beyond this application, nitriles themselves are not typically used as medications or therapeutic agents.

The testis, also known as the testicle, is a male reproductive organ that is part of the endocrine system. It is located in the scrotum, outside of the abdominal cavity. The main function of the testis is to produce sperm and testosterone, the primary male sex hormone.

The testis is composed of many tiny tubules called seminiferous tubules, where sperm are produced. These tubules are surrounded by a network of blood vessels, nerves, and supportive tissues. The sperm then travel through a series of ducts to the epididymis, where they mature and become capable of fertilization.

Testosterone is produced in the Leydig cells, which are located in the interstitial tissue between the seminiferous tubules. Testosterone plays a crucial role in the development and maintenance of male secondary sexual characteristics, such as facial hair, deep voice, and muscle mass. It also supports sperm production and sexual function.

Abnormalities in testicular function can lead to infertility, hormonal imbalances, and other health problems. Regular self-examinations and medical check-ups are recommended for early detection and treatment of any potential issues.

Adrenergic alpha-antagonists, also known as alpha-blockers, are a class of medications that block the effects of adrenaline and noradrenaline at alpha-adrenergic receptors. These receptors are found in various tissues throughout the body, including the smooth muscle of blood vessels, the heart, the genitourinary system, and the eyes.

When alpha-blockers bind to these receptors, they prevent the activation of the sympathetic nervous system, which is responsible for the "fight or flight" response. This results in a relaxation of the smooth muscle, leading to vasodilation (widening of blood vessels), decreased blood pressure, and increased blood flow.

Alpha-blockers are used to treat various medical conditions, such as hypertension (high blood pressure), benign prostatic hyperplasia (enlarged prostate), pheochromocytoma (a rare tumor of the adrenal gland), and certain types of glaucoma.

Examples of alpha-blockers include doxazosin, prazosin, terazosin, and tamsulosin. Side effects of alpha-blockers may include dizziness, lightheadedness, headache, weakness, and orthostatic hypotension (a sudden drop in blood pressure upon standing).

"Cells, cultured" is a medical term that refers to cells that have been removed from an organism and grown in controlled laboratory conditions outside of the body. This process is called cell culture and it allows scientists to study cells in a more controlled and accessible environment than they would have inside the body. Cultured cells can be derived from a variety of sources, including tissues, organs, or fluids from humans, animals, or cell lines that have been previously established in the laboratory.

Cell culture involves several steps, including isolation of the cells from the tissue, purification and characterization of the cells, and maintenance of the cells in appropriate growth conditions. The cells are typically grown in specialized media that contain nutrients, growth factors, and other components necessary for their survival and proliferation. Cultured cells can be used for a variety of purposes, including basic research, drug development and testing, and production of biological products such as vaccines and gene therapies.

It is important to note that cultured cells may behave differently than they do in the body, and results obtained from cell culture studies may not always translate directly to human physiology or disease. Therefore, it is essential to validate findings from cell culture experiments using additional models and ultimately in clinical trials involving human subjects.

Estrogen antagonists, also known as antiestrogens, are a class of drugs that block the effects of estrogen in the body. They work by binding to estrogen receptors and preventing the natural estrogen from attaching to them. This results in the inhibition of estrogen-mediated activities in various tissues, including breast and uterine tissue.

There are two main types of estrogen antagonists: selective estrogen receptor modulators (SERMs) and pure estrogen receptor downregulators (PERDS), also known as estrogen receptor downregulators (ERDs). SERMs, such as tamoxifen and raloxifene, can act as estrogen agonists or antagonists depending on the tissue type. For example, they may block the effects of estrogen in breast tissue while acting as an estrogen agonist in bone tissue, helping to prevent osteoporosis.

PERDS, such as fulvestrant, are pure estrogen receptor antagonists and do not have any estrogen-like activity. They are used primarily for the treatment of hormone receptor-positive breast cancer in postmenopausal women.

Overall, estrogen antagonists play an important role in the management of hormone receptor-positive breast cancer and other conditions where inhibiting estrogen activity is beneficial.

A radioligand assay is a type of in vitro binding assay used in molecular biology and pharmacology to measure the affinity and quantity of a ligand (such as a drug or hormone) to its specific receptor. In this technique, a small amount of a radioactively labeled ligand, also known as a radioligand, is introduced to a sample containing the receptor of interest. The radioligand binds competitively with other unlabeled ligands present in the sample for the same binding site on the receptor. After allowing sufficient time for binding, the reaction is stopped, and the amount of bound radioligand is measured using a technique such as scintillation counting. The data obtained from this assay can be used to determine the dissociation constant (Kd) and maximum binding capacity (Bmax) of the receptor-ligand interaction, which are important parameters in understanding the pharmacological properties of drugs and other ligands.

Histamine H3 antagonists, also known as inverse agonists, are a class of drugs that block the activity of histamine at the H3 receptor. Histamine is a naturally occurring neurotransmitter and autacoid involved in various physiological functions, including the modulation of wakefulness and arousal, regulation of food intake, and control of blood pressure and fluid balance.

The H3 receptor is primarily located in the central nervous system (CNS) and acts as an auto-receptor on histamine-containing neurons to regulate the release of histamine. By blocking the activity of these receptors, histamine H3 antagonists increase the release of histamine in the CNS, which can lead to increased wakefulness and arousal.

Histamine H3 antagonists have been studied for their potential therapeutic use in various neurological and psychiatric disorders, including narcolepsy, attention deficit hyperactivity disorder (ADHD), and Alzheimer's disease. However, further research is needed to fully understand the clinical benefits and safety of these drugs.

A ligand, in the context of biochemistry and medicine, is a molecule that binds to a specific site on a protein or a larger biomolecule, such as an enzyme or a receptor. This binding interaction can modify the function or activity of the target protein, either activating it or inhibiting it. Ligands can be small molecules, like hormones or neurotransmitters, or larger structures, like antibodies. The study of ligand-protein interactions is crucial for understanding cellular processes and developing drugs, as many therapeutic compounds function by binding to specific targets within the body.

Steroid 17-alpha-hydroxylase, also known as CYP17A1, is a cytochrome P450 enzyme that plays a crucial role in steroid hormone biosynthesis. It is located in the endoplasmic reticulum of cells in the adrenal glands and gonads. This enzyme catalyzes the 17-alpha-hydroxylation and subsequent lyase cleavage of pregnenolone and progesterone, converting them into dehydroepiandrosterone (DHEA) and androstenedione, respectively. These steroid intermediates are essential for the biosynthesis of both glucocorticoids and sex steroids, including cortisol, aldosterone, estrogens, and testosterone.

Defects in the CYP17A1 gene can lead to several disorders, such as congenital adrenal hyperplasia (CAH) due to 17-alpha-hydroxylase deficiency, which is characterized by decreased production of cortisol and sex steroids and increased mineralocorticoid levels. This condition results in sexual infantilism, electrolyte imbalances, and hypertension.

Dehydroepiandrosterone sulfate (DHEA-S) is a steroid hormone that is produced by the adrenal glands. It is a modified form of dehydroepiandrosterone (DHEA), which is converted to DHEA-S in the body for storage and later conversion back to DHEA or other steroid hormones, such as testosterone and estrogen. DHEA-S is often measured in the blood as a marker of adrenal function. It is also available as a dietary supplement, although its effectiveness for any medical purpose is not well established.

Aromatase is a enzyme that belongs to the cytochrome P450 superfamily, and it is responsible for converting androgens into estrogens through a process called aromatization. This enzyme plays a crucial role in the steroid hormone biosynthesis pathway, particularly in females where it is primarily expressed in adipose tissue, ovaries, brain, and breast tissue.

Aromatase inhibitors are used as a treatment for estrogen receptor-positive breast cancer in postmenopausal women, as they work by blocking the activity of aromatase and reducing the levels of circulating estrogens in the body.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Serotonin receptors are a type of cell surface receptor that bind to the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). They are widely distributed throughout the body, including the central and peripheral nervous systems, where they play important roles in regulating various physiological processes such as mood, appetite, sleep, memory, learning, and cognition.

There are seven different classes of serotonin receptors (5-HT1 to 5-HT7), each with multiple subtypes, that exhibit distinct pharmacological properties and signaling mechanisms. These receptors are G protein-coupled receptors (GPCRs) or ligand-gated ion channels, which activate intracellular signaling pathways upon serotonin binding.

Serotonin receptors have been implicated in various neurological and psychiatric disorders, including depression, anxiety, schizophrenia, and migraine. Therefore, selective serotonin receptor agonists or antagonists are used as therapeutic agents for the treatment of these conditions.

Estrogens are a group of steroid hormones that are primarily responsible for the development and regulation of female sexual characteristics and reproductive functions. They are also present in lower levels in males. The main estrogen hormone is estradiol, which plays a key role in promoting the growth and development of the female reproductive system, including the uterus, fallopian tubes, and breasts. Estrogens also help regulate the menstrual cycle, maintain bone density, and have important effects on the cardiovascular system, skin, hair, and cognitive function.

Estrogens are produced primarily by the ovaries in women, but they can also be produced in smaller amounts by the adrenal glands and fat cells. In men, estrogens are produced from the conversion of testosterone, the primary male sex hormone, through a process called aromatization.

Estrogen levels vary throughout a woman's life, with higher levels during reproductive years and lower levels after menopause. Estrogen therapy is sometimes used to treat symptoms of menopause, such as hot flashes and vaginal dryness, or to prevent osteoporosis in postmenopausal women. However, estrogen therapy also carries risks, including an increased risk of certain cancers, blood clots, and stroke, so it is typically recommended only for women who have a high risk of these conditions.

Endothelin receptors are a type of G protein-coupled receptor that bind to endothelin, a potent vasoconstrictor peptide. There are two main types of endothelin receptors: ETA and ETB. ETA receptors are found in vascular smooth muscle cells and activate phospholipase C, leading to an increase in intracellular calcium and subsequent contraction of the smooth muscle. ETB receptors are found in both endothelial cells and vascular smooth muscle cells. In endothelial cells, ETB receptor activation leads to the release of nitric oxide and prostacyclin, which cause vasodilation. In vascular smooth muscle cells, ETB receptor activation causes vasoconstriction through a mechanism that is not fully understood.

Endothelin receptors play important roles in regulating blood flow, vascular remodeling, and the development of cardiovascular diseases such as hypertension and heart failure. They are also involved in the regulation of cell growth, differentiation, and apoptosis in various tissues.

Cholestenone 5 alpha-reductase is an enzyme that plays a role in the conversion of cholesterol and other steroid hormones in the body. Specifically, it catalyzes the reduction of 5,7-dihydroxycholest-4-en-3-one (also known as cholestenone) to 5α-androstan-3α,17β-diol, which is a precursor to the male sex hormone testosterone.

This enzyme is found in various tissues throughout the body, including the prostate gland, skin, and liver. In the prostate gland, 5 alpha-reductase helps regulate the growth and function of the gland by converting testosterone to dihydrotestosterone (DHT), a more potent form of the hormone.

Inhibitors of 5 alpha-reductase are sometimes used as medications to treat conditions such as benign prostatic hyperplasia (BPH) and male pattern baldness, as reducing DHT levels can help alleviate symptoms associated with these conditions.

Adrenergic beta-2 receptor antagonists, also known as beta-2 adrenergic blockers or beta-2 antagonists, are a class of medications that block the action of epinephrine (adrenaline) and other catecholamines at beta-2 adrenergic receptors. These receptors are found in various tissues throughout the body, including the lungs, blood vessels, and skeletal muscles.

Beta-2 adrenergic receptor antagonists are primarily used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). They work by relaxing the smooth muscle in the airways, which helps to reduce bronchoconstriction and improve breathing.

Some examples of beta-2 adrenergic receptor antagonists include:

* Butoxamine
* ICI 118,551
* Salbutamol (also a partial agonist)
* Terbutaline (also a partial agonist)

It's important to note that while these medications are called "antagonists," some of them can also act as partial agonists at beta-2 receptors, meaning they can both block the action of catecholamines and stimulate the receptor to some degree. This property can make them useful in certain clinical situations, such as during an asthma attack or preterm labor.

N-Methyl-D-Aspartate (NMDA) receptors are a type of ionotropic glutamate receptor, which are found in the membranes of excitatory neurons in the central nervous system. They play a crucial role in synaptic plasticity, learning, and memory processes. NMDA receptors are ligand-gated channels that are permeable to calcium ions (Ca2+) and other cations.

NMDA receptors are composed of four subunits, which can be a combination of NR1, NR2A-D, and NR3A-B subunits. The binding of the neurotransmitter glutamate to the NR2 subunit and glycine to the NR1 subunit leads to the opening of the ion channel and the influx of Ca2+ ions.

NMDA receptors have a unique property in that they require both agonist binding and membrane depolarization for full activation, making them sensitive to changes in the electrical activity of the neuron. This property allows NMDA receptors to act as coincidence detectors, playing a critical role in synaptic plasticity and learning.

Abnormal functioning of NMDA receptors has been implicated in various neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and chronic pain. Therefore, NMDA receptors are a common target for drug development in the treatment of these conditions.

... is an antiandrogen, or antagonist of the androgen receptor (AR), the biological target of androgens such as ... Clascoterone is a steroidal antiandrogen, or antagonist of the androgen receptor (AR), the biological target of androgens such ... Lerner LJ (1975). "Androgen antagonists". Pharmacol Ther B. 1 (2): 217-31. doi:10.1016/0306-039x(75)90006-9. PMID 772705. "Drug ... is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro". J Drugs Dermatol. 18 (2): 197-201. PMID 30811143. Rosette ...
Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues". Pharmacology & ... Lerner LJ (1975). "Androgen antagonists". Pharmacology & Therapeutics B. 1 (2): 217-231. doi:10.1016/0306-039X(75)90006-9. PMID ... 11α-OHP was investigated as a topical antiandrogen for the treatment of androgen-dependent skin conditions in the early 1950s, ...
Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues". Pharmacol Ther. 24 (3 ... Singh, Shankar; Gauthier, Sylvain; Labrie, Fernand (2000). "Androgen Receptor Antagonists (Antiandrogens) Structure-Activity ... In addition, although CPA reduces androgen production in the gonads, it can increase the production of adrenal androgens, in ... Similar depressive changes have been observed with castration, and may be a consequence of androgen deprivation in men. In ...
... is an antiandrogen, or an antagonist of the androgen receptor (AR), the biological target of the androgen sex ... ISBN 978-3-642-80859-3. Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues ... Thus we are left with CPA as the only anti-androgen that is already on the market in several countries. Elks J (14 November ... eds.). Androgens II and Antiandrogens / Androgene II und Antiandrogene. Springer Science & Business Media. pp. 491-492, 516-517 ...
"Androgen antagonists in androgen target tissues". Pharmacol. Ther. 24 (3): 367-400. doi:10.1016/0163-7258(84)90010-x. PMID ... It is a selective antagonist of the androgen receptor and consequently has progonadotropic effects by increasing gonadotropin ... Singh SM, Gauthier S, Labrie F (2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Curr ... RU-58642 RU-58841 "Compositions and methods for inhibiting the action of androgens". Tindall DJ, Chang CH, Lobl TJ, Cunningham ...
Ran F, Xing H, Liu Y, Zhang D, Li P, Zhao G (2015). "Recent Developments in Androgen Receptor Antagonists". Archiv der ... RU-59063 is a nonsteroidal androgen or selective androgen receptor modulator (SARM) which was first described in 1994 and was ... RU-59063 has high affinity for the human androgen receptor (AR) (Ki = 2.2 nM; Ka = 5.4 nM) and 1,000-fold selectivity for the ... Liu B, Su L, Geng J, Liu J, Zhao G (2010). "Developments in nonsteroidal antiandrogens targeting the androgen receptor". ...
They are typically selective and full or silent antagonists of the androgen receptor (AR) and act by directly blocking the ... ISBN 978-1-60761-471-5. Singh SM, Gauthier S, Labrie F (2000). "Androgen receptor antagonists (antiandrogens): structure- ... Singh SM, Gauthier S, Labrie F (2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Curr ... An over-the-counter histamine H2 receptor antagonist that also shows very weak activity as an AR antagonist. Also inhibits ...
They are typically antagonists of the androgen receptor (AR) and act both by blocking the effects of androgens like ... Specifically acts as an AR antagonist, weak antigonadotropin, and weak steroidogenesis inhibitor. Used for androgen-dependent ... There are many different androgen blockers used for transition care. Spironolactone, an aldosterone receptor antagonist, is ... ISBN 978-1-60761-471-5. Singh SM, Gauthier S, Labrie F (2000). "Androgen receptor antagonists (antiandrogens): structure- ...
"Androgen receptor antagonists (antiandrogens): structure-activity relationships". Curr. Med. Chem. 7 (2): 211-47. doi:10.2174/ ... It shows 163% of the affinity of testosterone for the androgen receptor and negligible affinity for other steroid hormone ... synthesis and biological profile of high-affinity ligands for the androgen receptor". J. Steroid Biochem. Mol. Biol. 48 (1): ...
... acts as a selective antagonist of the androgen receptor (AR), competing with androgens like testosterone and ... Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP (July 2002). "Bicalutamide functions as an androgen receptor antagonist by ... Sundblad C, Landén M, Eriksson T, Bergman L, Eriksson E (February 2005). "Effects of the androgen antagonist flutamide and the ... In contrast to GnRH agonists, GnRH antagonists don't cause an initial androgen surge, and are gradually replacing GnRH agonists ...
321-. ISBN 978-1-901865-55-4. Singh, Shankar; Gauthier, Sylvain; Labrie, Fernand (2000). "Androgen Receptor Antagonists ( ...
Similarly to flutamide, AA560 is a selective antagonist of the androgen receptor (AR) and consequently shows progonadotropic ... Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity ... Rasmusson GH (September 1986). "Chemical Control of Androgen Action.". Annual Reports in Medicinal Chemistry. Vol. 21. Academic ...
CPA is a potent competitive antagonist of the androgen receptor (AR), the biological target of androgens such as testosterone ... It has been said that in combined androgen blockade regimens with castration and CPA as the AR antagonist for prostate cancer, ... Androgens: Pharmacodynamics and antagonists. Biochemical and biological studies with 4-aza-steroidal 5 alpha-reductase ... ISBN 978-1-4496-8695-6. Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): ...
Antiandrogens that directly block the androgen receptor are known as androgen receptor antagonists or blockers, while ... nonsteroidal antiandrogens are highly selective for the androgen receptor and act as pure androgen receptor antagonists. ... It works as an antiandrogen mainly by acting as an androgen receptor antagonist. The medication is also a weak steroidogenesis ... In addition to its actions as an antigonadotropin, cyproterone acetate is an androgen receptor antagonist. However, this action ...
Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity ... Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP (1987). "Towards the mapping of the progesterone and androgen ... ISBN 978-1-4831-4566-2. R-2956 [41-43], a dimethyl derivative of an extremely potent androgen, R 1881 [44], is a powerful ... Takeda AN, Pinon GM, Bens M, Fagart J, Rafestin-Oblin ME, Vandewalle A (2007). "The synthetic androgen methyltrienolone (r1881 ...
In fact, it is actually an antagonist of the androgen receptor (AR), and hence has antiandrogenic activity. The antiandrogenic ... 63-. ISBN 978-3-319-20185-6. Singh SM, Gauthier S, Labrie F (2000). "Androgen receptor antagonists (antiandrogens): structure- ... It may be able to improve androgen-dependent symptoms such as acne and hirsutism. Metabolites of dienogest, such as 9α,10β- ... Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP (1987). "Towards the mapping of the progesterone and androgen ...
... acts as a selective antagonist of the androgen receptor (AR), preventing the effects of androgens like testosterone ... Nilutamide acts as a selective competitive silent antagonist of the AR (IC50 = 412 nM), which prevents androgens like ... Kemppainen JA, Wilson EM (July 1996). "Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen ... 11-. ISBN 978-981-256-920-2. Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): ...
The medication is a silent antagonist of the androgen receptor. RU-56187 is 3- to 10-fold more potent as an antiandrogen than ... RU-57073 RU-58642 RU-59063 Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): ... "Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and ... It shows 92% of the affinity of testosterone for the androgen receptor and negligible affinity for other steroid hormone ...
Kemppainen JA, Wilson EM (July 1996). "Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen ... Rathkopf D, Scher HI (2013). "Androgen receptor antagonists in castration-resistant prostate cancer". Cancer Journal. 19 (1): ... ISBN 978-1-60327-829-4. Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): ... "Androgen receptor antagonists for prostate cancer therapy". Endocrine-Related Cancer. 21 (4): T105-18. doi:10.1530/ERC-13-0545 ...
Kemppainen JA, Wilson EM (July 1996). "Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen ... Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity ... a steroidal androgen receptor antagonist". Journal of Steroid Biochemistry. 33 (6): 1133-1138. doi:10.1016/0022-4731(89)90420-2 ... differential effects on high-androgen responder and low-androgen responder muscle groups". Endocrinology. 154 (12): 4594-4606. ...
... is a selective competitive antagonist of the androgen receptor (AR), although it is described as an "only relatively weak ... ISBN 978-1-4831-6510-3. Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): ... is not an androgen antagonist within the central nervous system". Steroids. 34 (2): 139-149. doi:10.1016/0039-128X(79)90043-6. ... On the basis of animal research, BOMT does not appear to act as an AR antagonist in central nervous system tissues, and in ...
Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP (July 2002). "Bicalutamide functions as an androgen receptor antagonist by ... Kawahara T, Minamoto H (2014). "Androgen Receptor Antagonists in the Treatment of Prostate Cancer". Clinical Immunology, ... Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity ... It works by selectively blocking the androgen receptor (AR), the biological target of the androgen sex hormones testosterone ...
53-. ISBN 978-3-642-88429-0. Jost A (1971). "Use of androgen antagonists and antiandrogens in studies on sex differentiation". ... Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity ... These conditions are worsened by the presence of androgens, and by suppressing androgen levels and blocking their actions, CPA ... Chemical Control of Androgen Action. Annual Reports in Medicinal Chemistry. Vol. 21. pp. 179-188. doi:10.1016/S0065-7743(08) ...
ISBN 978-3-527-30247-5. Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): ...
Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity ... 27 November 2013). Androgens II and Antiandrogens / Androgene II und Antiandrogene. Springer Science & Business Media. pp. 351 ... Handelsman DJ (October 2020). "Androgen Physiology, Pharmacology, Use and Misuse". In Feingold KR, Anawalt B, Boyce A, Chrousos ... Zouboulis CC, Degitz K (2004). "Androgen action on human skin -- from basic research to clinical significance". Experimental ...
Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity ... List of androgens/anabolic steroids Hill RA, Makin HL, Kirk DN, Murphy GM (23 May 1991). Dictionary of Steroids. CRC Press. pp ... Androgens and anabolic steroids, Androstanes, Enones, All stub articles, Steroid stubs, Genito-urinary system drug stubs, ...
Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity ... Rosterolone is a derivative of mesterolone, which, in contrast, is an androgen and anabolic steroid. Steroidal antiandrogen - ...
Non-steroidal selective androgen receptor antagonists, developed as a treatment for androgen-sensitive prostate cancer, are ... Enzalutamide is an antiandrogen, and acts as an antagonist of the androgen receptor, the biological target of androgens like ... Enzalutamide acts as a selective silent antagonist of the androgen receptor (AR), the biological target of androgens like ... Rathkopf D, Scher HI (2013). "Androgen receptor antagonists in castration-resistant prostate cancer". Cancer Journal. 19 (1): ...
... is an antiandrogen, and acts as an antagonist of the androgen receptor, the biological target of androgens like ... Apalutamide acts as a selective competitive silent antagonist of the androgen receptor (AR), via the ligand-binding domain, and ... Kawahara T, Miyamoto H (June 2014). "Androgen Receptor Antagonists in the Treatment of Prostate Cancer". Clinical Immunology, ... Rathkopf D, Scher HI (2013). "Androgen receptor antagonists in castration-resistant prostate cancer". Cancer Journal. 19 (1): ...
... - AdisInsight Research programme: androgen receptor antagonists (EM-4350, EM-5855, EM-6537) - AdisInsight v t e v t e ( ... Gauthier S, Martel C, Labrie F (October 2012). "Steroid derivatives as pure antagonists of the androgen receptor". J. Steroid ... The drug acts as a potent and selective competitive antagonist of the androgen receptor (AR). Unlike other steroidal ... Fujii S, Kagechika H (June 2019). "Androgen receptor modulators: a review of recent patents and reports (2012-2018)". Expert ...
... to detect Androgen Receptor Agonists and Antagonists. The ARTA assay methods are mechanistically and functionally similar test ... This Test Guideline describes in vitro assays, which use Androgen Receptor TransActivation (ARTA) to detect Androgen Receptor ... Stably Transfected Human Androgen Receptor Transcriptional Activation Assay for Detection of Androgenic Agonist and Antagonist ... Stably Transfected Human Androgen Receptor Transcriptional Activation Assay for Detection of Androgenic Agonist and Antagonist ...
JJ-74-138 is a Novel Noncompetitive Androgen Receptor Antagonist Ryan N. Cole; Ryan N. Cole ... Identification of novel androgen receptor (AR) antagonists may lead to urgently needed new treatments for patients with ... A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR (F876L) nuclear import and function ... Small molecule antagonists of the nuclear androgen receptor for the treatment of castration-resistant prostate cancer ...
... Computational Biology and Chemistry, 92, art. no. 107490. ... several environmental pollutants are known to disrupt androgen signaling via binding to androgen receptor (AR) or indirectly ... Reporter assay with MDA-kb2 cells showed that linuron, procymidone, bicalutamide and enzalutamide can inhibit androgen mediated ... In addition to many other compounds that have been shown to alter androgen signaling, ...
Novel Androgen Receptor Antagonists. Enzalutamide, a second-generation androgen receptor inhibitor initially approved for the ... Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent ... Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent ... Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 2020; 382 (23) 2187-2196 ...
Clascoterone is an antiandrogen, or antagonist of the androgen receptor (AR), the biological target of androgens such as ... Clascoterone is a steroidal antiandrogen, or antagonist of the androgen receptor (AR), the biological target of androgens such ... Lerner LJ (1975). "Androgen antagonists". Pharmacol Ther B. 1 (2): 217-31. doi:10.1016/0306-039x(75)90006-9. PMID 772705. "Drug ... is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro". J Drugs Dermatol. 18 (2): 197-201. PMID 30811143. Rosette ...
Androgen Antagonists / adverse effects * Androgen Antagonists / therapeutic use* * Antineoplastic Agents, Hormonal / adverse ... Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis Ann Intern Med ...
Androgen Antagonists / pharmacology* * Antineoplastic Agents, Phytogenic / pharmacology* * Apoptosis / drug effects* * Cell ... These four pomegranate compounds inhibited DHT-stimulated androgen receptor nuclear accumulation and the expression of the ... and pro-apoptotic effects of 13 pure compounds found in the pomegranate in androgen-dependent LNCaP human prostate cancer cells ... exhibited potent growth inhibitory activities in androgen-dependent LNCaP cells, which appear to be mediated by both ...
N2 - Background: Androgen deprivation therapy (ADT) plays a crucial role in treatment of advanced prostate cancer (PCa). The ... Conclusion: GnRH antagonists have a lower risk of treatment related cardiovascular events compared to GnRH agonists. Risks ... AB - Background: Androgen deprivation therapy (ADT) plays a crucial role in treatment of advanced prostate cancer (PCa). The ... Background: Androgen deprivation therapy (ADT) plays a crucial role in treatment of advanced prostate cancer (PCa). The ...
Pharmacological Actions : Androgen Antagonists. [+] These pilot data suggest that a flaxseed-supplemented, fat-restricted diet ... Soy product intake is inversely associated with serum androgen and estrogen concentrations in Japanese men. Jan 01, 2000. ... These results suggest a potential role for ginseng in modulating salivary androgen levels.May 27, 2020. ... Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. Jul 07, 2009. ...
An androgen receptor N-terminal domain antagonist for treating prostate cancer. The Journal of clinical investigation, 2013 ... Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity ... Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain ... Blocking androgen receptor (AR) transcriptional activity by androgen deprivation therapy (ADT) improves the response to ...
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration- ... Apalutamide, a nonsteroidal potent androgen receptor antagonist, was safe and effective in patients with non-metastatic ...
Clascoterone Topical Cream 1%: A Novel, Topical, Local, Selective Androgen Antagonist: Results from two Phase 3 Studies ... Biological profile of cortexolone 17 alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist ... Clascoterone Topical Cream, 1%: A Novel, Topical, Local, Selective Androgen Receptor Antagonist: Results from Two Phase 3 ... Clascoterone is the first topical androgen receptor inhibitor and is available in two formulations. A 1% cream is under ...
... antagonist, ORIC-101, reversing GR-mediated resistance to an androgen receptor (AR) degrader. ... antagonist, ORIC-101, reversing GR-mediated resistance to an androgen receptor (AR) degrader. ... ORIC-101 was shown to completely reverse these effects and block tumor cell growth and androgen-regulated gene expression. ... ORIC-101 was shown to completely reverse these effects and block tumor cell growth and androgen-regulated gene expression. ...
Androgen antagonists: Potential role in prostate cancer prevention. Urology. 2001 Apr. 57(4 Suppl 1):64-7. [QxMD MEDLINE Link] ... Tamoxifen and raloxifene are selective estrogen receptor modulators (SERMs) that have both estrogen agonist and antagonist ...
Androgen Antagonists); 0 (Benzhydryl Compounds); 0 (Carcinogens); 0 (Epoxy Compounds); 0 (Receptors, Androgen); 0 (bisphenol F ... These results suggest that these chlorohydroxy compounds of BADGE and BFDGE act as androgen antagonist through the process of ... Androgen Antagonists/pharmacology, Animals, Benzhydryl Compounds, CHO Cells, Carcinogens/pharmacology, Cricetinae, Cricetulus, ... One stably expresses luciferase with induction of androgen. The other stably expresses luciferase without androgen induction. ...
Androgen Receptor Antagonists May Meet Unmet Need in Triple-Negative Breast Cancer. Although there are no androgen receptor ... antagonists currently approved for the treatment of breast cancer, clinical trials indicate that these agents benefit some ...
Singh, SM, Gauthier, S, Labrie, F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med ... In vivo mouse models of androgen blockade or androgen resistance. Androgen receptor blockade was carried out in intact male ... Androgens only affected B cell development in chimeric mice with androgen-sensitive stromal cells. These experiments suggest ... Bone marrow B lymphocyte populations in chimeric mice in an androgen-deficient state (open bars) and after androgen ...
Natural Steroids and Androgen Antagonists used as Neuroprotection in Common Neurological Disorders. Journal: CNS & Neurological ...
Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents with Congenital Adrenal Hyperplasia. May 22, ... Predictors of Ongoing Androgen Abuse. A Prospective Two Year Follow Up of 100 Male Androgen Abusers. August 15, 2023 ... Clinical impact of androgen receptor-suppressing miR-146b expression in papillary thyroid cancer aggressiveness. May 23, 2023 ... The Role of Androgen Receptors in Thyroid Cancer Biology: Beyond Sexual Dimorphism. July 15, 2023 ...
Androgen Antagonists. Receptors, Androgen. Public MeSH Note. 1963. History Note. 1963. Entry Combination. antagonists & ... Androgen Androgen Effect Androgen Effects Androgen Receptor Agonist Androgen Receptor Agonists Androgenic Agents Androgenic ... Androgen Effect Related Concept UI. M0556150. Registry Number. 0. Terms. Androgen Effect Preferred Term Term UI T787964. Date03 ... Androgens Preferred Concept UI. M0001106. Registry Number. 0. Scope Note. Compounds that interact with ANDROGEN RECEPTORS in ...
Non-steroidal androgen receptor antagonist. 3392. VKGILS-NH2 Control peptide for SLIGKV-NH2 (Cat. No. 3010). ...
... and LAR was sensitive to the androgen receptor (AR) antagonist bicalutamide. This preclinical study potentially represents a ... Blockade of the androgen receptor and the folate receptor, inhibition of the PI3K/mTOR and MEK [mitogen-activated protein/ ... and luminal androgen receptor (LAR) subtypes. Representative cell lines of each subtype have responded to different therapies. ...
Progesterone, androgen and estrogen receptor agonists/antagonists. Network. nt06019 Steroid hormone biosynthesis. nt06227 ... Androgens. C00535 Testosterone. Lipids [BR:br08002]. ST Sterol lipids. ST02 Steroids. ST0202 C19 steroids (androgens) and ... Androgens. C00280 Androstenedione. Lipids [BR:br08002]. ST Sterol lipids. ST02 Steroids. ST0202 C19 steroids (androgens) and ... Androgens. Testosterone. D00075 Testosterone (JAN/USP). Classification of Japanese OTC drugs [BR:br08313]. Agents for ...
The names of the treatment interventions involved in this study are: - Androgen receptor antagonist monotherapy. - PSMA PET/CT ... Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or ... Androgens are a group of hormones that play a role in male traits and reproductive activity. The names of the study ... A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer. Trial Description: This research study is ...
"SIRT1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor". ...
  • Androgen deprivation therapy (ADT) combined with docetaxel or antiandrogens (abiraterone, enzalutamide, or apalutamide) improved the outcomes in men with metastatic hormone-sensitive prostate cancer (mHSPC). (thieme-connect.com)
  • 1 ] The upfront management of men with metastatic hormone-sensitive prostate cancer (mHSPC) had been with only androgen deprivation therapy (ADT), for a long time, either with medical or surgical castration. (thieme-connect.com)
  • Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? (uni-luebeck.de)
  • Background: Androgen deprivation therapy (ADT) plays a crucial role in treatment of advanced prostate cancer (PCa). (uni-luebeck.de)
  • Dive into the research topics of 'Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? (uni-luebeck.de)
  • Blocking androgen receptor (AR) transcriptional activity by androgen deprivation therapy (ADT) improves the response to radiotherapy for intermediate and high risk prostate cancer. (bcgsc.ca)
  • The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk factors in Black men diagnosed with prostate cancer and are undergoing androgen deprivation therapy (ADT), and whether it will also improve physical fitness and function, body composition, and outcomes such as quality of life, cancer symptoms, and self-esteem. (dana-farber.org)
  • UNLABELLED: Inhibiting the androgen receptor (AR), a ligand-activated transcription factor, with androgen deprivation therapy is a standard-of-care treatment for metastatic prostate cancer. (cam.ac.uk)
  • In the trial, this agent was highly tolerable across all tested dose levels, with adverse effects (AEs) largely resembling those of other androgen receptor (AR) antagonists and androgen deprivation therapy (ADT), Laccetti explains. (onclive.com)
  • The new Phase III study ARASENS will evaluate the safety and efficacy of the compound in combination with standard androgen deprivation therapy (ADT) and the chemotherapy docetaxel in men with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are starting first line hormone therapy. (orion.fi)
  • Upon relapse when the disease will metastasize or spread, androgen deprivation therapy (ADT) is the cornerstone of treatment for this hormone-sensitive disease. (orion.fi)
  • Drugs commonly used for prostate cancer include luteinizing hormone-releasing hormone (LHRH) agonists, LHRH antagonists and androgen synthesis inhibitors. (sutterhealth.org)
  • Prior use of other 2nd generation CYP17 inhibitors and androgen receptor antagonists are allowed in addition to abiraterone or enzalutamide. (mayo.edu)
  • We analyzed here the molecular mechanism of the interaction between the human AR Ligand Binding Domain (hAR-LBD) and two environmental pollutants, linuron (a herbicide) and procymidone (a pesticide), and compared with the steroid agonist dihydrotestosterone (DHT) and well-known hAR antagonists bicalutamide and enzalutamide. (iste.edu.tr)
  • Reporter assay with MDA-kb2 cells showed that linuron, procymidone, bicalutamide and enzalutamide can inhibit androgen mediated activation of luciferase activity. (iste.edu.tr)
  • and LAR was sensitive to the androgen receptor (AR) antagonist bicalutamide. (cancernetwork.com)
  • Prior treatment with first-generation AR antagonists (i.e., bicalutamide, nilutamide, flutamide) before abiraterone or enzalutamide is allowed. (mayo.edu)
  • Recently, our laboratory discovered selective androgen receptor modulators, which structurally resemble the nonsteroidal AR antagonists bicalutamide and hydroxyflutamide but act as agonists for the androgen receptor in a tissue-selective manner. (rcsb.org)
  • To investigate why subtle structural changes to both the ligand and the receptor (i.e. mutations) result in drastic changes in activity, we studied structure-activity relationships for nonsteroidal AR ligands through crystallography and site-directed mutagenesis, comparing bound conformations of R-bicalutamide, hydroxyflutamide, and two previously reported nonsteroidal androgens, S-1 and R-3. (rcsb.org)
  • This agent targets androgen receptors in sebocytes and hair papilla cells within the skin's pilosebaceous unit, intervenes at multiple and different points in acne pathogenesis, and inhibits dihydrotestosterone-stimulated signaling downstream of the androgen receptors. (aadhighlights.com)
  • These experiments suggest that effects of androgens on developing B cells are mediated through androgen receptors in bone marrow stromal cells. (jci.org)
  • Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE . (nih.gov)
  • Antiandrogens bind to androgen receptors and competitively inhibit their interaction with testosterone and dihydrotestosterone. (medscape.com)
  • It was initially identified as an androgen-induced growth factor and plays a role in regulating growth of human BREAST NEOPLASMS and PROSTATIC NEOPLASMS. (bvsalud.org)
  • Pin1 inhibition improves the efficacy of ralaniten compounds that bind to the N-terminal domain of androgen receptor. (bcgsc.ca)
  • Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays. (bvsalud.org)
  • ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. (oricpharma.com)
  • Selective A 2A antagonist. (tocris.com)
  • The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with enzalutamide or abiraterone. (mayo.edu)
  • Apalutamide, a nonsteroidal potent androgen receptor antagonist, was safe and effective in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic-CRPC (mCRPC) in global studies. (endourology.ph)
  • Collectively, our study reveals that the potent androgen MeT can increase the immunogenicity of prostate cancer cells via a viral mimicry response, a finding that has potential implications for the development of strategies to sensitize this cancer type to immunotherapies. (cam.ac.uk)
  • SIGNIFICANCE: Our study demonstrates that potent androgen stimulation of prostate cancer cells can elicit a viral mimicry response, resulting in enhanced IFN signaling. (cam.ac.uk)
  • Clascoterone is the first topical androgen receptor inhibitor and is available in two formulations. (aadhighlights.com)
  • Clascoterone is a topical androgen receptor inhibitor under investigation for the treatment of acne. (aadhighlights.com)
  • Can a Topical Androgen Villain Aid With Acne? (thenewboyz.com)
  • Can a topical androgen antagonist help with acne? (thenewboyz.com)
  • Patients must have undergone orchiectomy, or have been on LHRH agonists or antagonists, for at least 3 months prior to drug initiation. (mayo.edu)
  • Patients on LHRH agonists/antagonists must remain on these agents for the duration of the study. (mayo.edu)
  • Here, we show that (+)-JJ-74-138 is more potent than JJ-450 in the inhibition of androgen-independent AR activity in enzalutamide-resistant LN95 cells. (aacrjournals.org)
  • Likewise, it is significantly more efficacious as an antiandrogen than other AR antagonists such as enzalutamide and spironolactone in scalp dermal papilla cells and sebocytes in vitro. (wikipedia.org)
  • Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants. (bcgsc.ca)
  • Enzalutamide, a second-generation androgen receptor (AR) antagonist, has demonstrated clinical benefit in men with prostate cancer. (duke.edu)
  • Incidence of severe cardiac adverse events may be lower with the use of degarelix compared with GnRH agonists,[ 5 ] an ongoing prospective trial is comparing the risk of cardiovascular events with the use of GnRH agonists and antagonists. (thieme-connect.com)
  • As a whole, these studies provide critical new insight for receptor-based drug design of nonsteroidal AR agonists and antagonists. (rcsb.org)
  • Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-β1. (oregonstate.edu)
  • Flutamide is an androgen receptor (AR) antagonist approved by the United States Food and Drug Administration for the treatment of prostate cancer. (oregonstate.edu)
  • Objectives: Review of current evidence on potential differences regarding the cardiovascular risk profile of gonadotropin-releasing hormone (GnRH) agonists compared to GnRH antagonists. (uni-luebeck.de)
  • Tyagi R.K. Mechanisms of inhibition of transcriptional activity of androgen receptor by antagonists/endocrine disruptors CSIR , (2003-2006). (jnu.ac.in)
  • Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. (greenmedinfo.com)
  • Both metabolites exhibit minimal anti-androgen activity and weak glucocorticoid properties [1,2]. (aadhighlights.com)
  • 3 ] [ 4 ] GnRH antagonist degarelix is not associated with this surge of LH and can be a substitute to a GnRH agonist when a rapid fall in serum testosterone is necessary. (thieme-connect.com)
  • Overall, a decreased incidence of cardiovascular events was reported for GnRH antagonists compared to GnRH agonists. (uni-luebeck.de)
  • Conclusion: GnRH antagonists have a lower risk of treatment related cardiovascular events compared to GnRH agonists. (uni-luebeck.de)
  • In this study, we investigated the growth inhibitory, antiandrogenic, and pro-apoptotic effects of 13 pure compounds found in the pomegranate in androgen-dependent LNCaP human prostate cancer cells. (nih.gov)
  • Clascoterone is an antiandrogen, or antagonist of the androgen receptor (AR), the biological target of androgens such as testosterone and dihydrotestosterone. (wikipedia.org)
  • One mechanism underlying CRPC and resistance to hormonal therapies is the expression of constitutively active splice variant(s) of androgen receptor (AR-Vs) that lack its C-terminus ligand-binding domain. (bcgsc.ca)
  • The most effective option is to discover an approach that will certainly help to balance our hormonal agents so that there is no excess manufacturing of androgen or various other hormone which can cause acne. (thenewboyz.com)
  • Our findings suggest testosterone and other androgen hormones may help shape the gut microbiome," says senior author Varykina G Thackray, PhD, of the University of California San Diego School of Medicine, La Jolla, in a press statement issued by the Endocrine Society. (medscape.com)
  • In addition to many other compounds that have been shown to alter androgen signaling, several environmental pollutants are known to disrupt androgen signaling via binding to androgen receptor (AR) or indirectly affecting the androgen synthesis. (iste.edu.tr)
  • The mechanism by which the androgen receptor (AR) distinguishes between agonist and antagonist ligands is poorly understood. (rcsb.org)
  • Identification of novel androgen receptor (AR) antagonists may lead to urgently needed new treatments for patients with prostate cancer resistant to current AR antagonists. (aacrjournals.org)
  • Clinically approved AR antagonists compete with dihydrotestosterone (DHT) for binding to the ligand-binding domain (LBD) of AR, and patients eventually develop resistance to these treatments. (aacrjournals.org)
  • An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer. (endourology.ph)
  • We employed in vitro cultures and two in vivo models to investigate whether androgens exert these effects directly on marrow lymphoid precursors or whether actions on marrow stromal elements are required. (jci.org)
  • The presentation will highlight preclinical data in prostate cancer cell lines that demonstrate the company's glucocorticoid receptor (GR) antagonist, ORIC-101, reversing GR-mediated resistance to an androgen receptor (AR) degrader. (oricpharma.com)
  • These four pomegranate compounds inhibited DHT-stimulated androgen receptor nuclear accumulation and the expression of the androgen receptor-dependent genes prostate specific antigen and steroid 5α-reductase type 1 at concentrations ≥10 μM. (nih.gov)
  • Clascoterone, also known as cortexolone 17α-propionate or 11-deoxycortisol 17α-propionate, as well as 17α,21-dihydroxyprogesterone 17α-propionate or 17α,21-dihydroxypregn-4-en-3,20-dione 17α-propionate, is a synthetic pregnane steroid and a derivative of progesterone and 11-deoxycortisol (cortexolone). (wikipedia.org)
  • Soy product intake is inversely associated with serum androgen and estrogen concentrations in Japanese men. (greenmedinfo.com)
  • This study exploited a potent synthetic androgen, methyltestosterone (MeT), to investigate AR agonist-induced growth inhibition. (cam.ac.uk)
  • In conclusion, punicic acid, the main constituent of pomegranate seed (70-80%), exhibited potent growth inhibitory activities in androgen-dependent LNCaP cells, which appear to be mediated by both antiandrogenic and pro-apoptotic mechanisms. (nih.gov)
  • ORIC-101 was shown to completely reverse these effects and block tumor cell growth and androgen-regulated gene expression. (oricpharma.com)
  • Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. (dana-farber.org)
  • JJ-74-138 inhibited mRNA expression of AR and ARv7 target genes and reduced AR level in the nucleus in the absence of androgens. (aacrjournals.org)
  • Alpha-receptor antagonist medications potentially interfere with iris muscle dilation, resulting in difficult lens removal and possibly increasing complications. (urotoday.com)
  • Also, this analogue noncompetitively inhibited androgen-stimulated AR activity in C4-2, LN95, and 22Rv1 CRPC cells. (aacrjournals.org)
  • Immature B cells from normal mouse bone marrow were not responsive to the suppressive effect of androgens unless they were cocultured with marrow stromal cells or with supernatants from androgen-treated stromal cells, suggesting that the androgen effects are exerted through marrow stromal elements by production of a diffusible mediator. (jci.org)
  • The stromal cell requirement for androgen-mediated effects was confirmed in vivo by experiments using chimeric animals created by bone marrow transplantation in which androgen receptor expression was restricted to either the stromal or lymphoid cells of the bone marrow. (jci.org)
  • Androgens only affected B cell development in chimeric mice with androgen-sensitive stromal cells. (jci.org)
  • ODM-201 (BAY-1841788) is an investigational oral androgen receptor (AR) antagonist that has a unique chemical structure designed to block the growth of cancer cells through binding to the AR with high affinity and inhibiting the receptor function. (orion.fi)
  • A topical application of an androgen antagonist is made to assist stop and turn around the androgen hormone which is understood to cause acnes and also is accountable for causing loss of hair as well. (thenewboyz.com)
  • AR antagonists are currently used to treat prostate cancer. (rcsb.org)
  • Small Indels in the Androgen Receptor Gene: Phenotype Implications and Mechanisms of Mutagenesis. (medscape.com)
  • 2] Leh-mann et al have described six subtypes of TNBC based on gene expression profiles,[3] including two basal-like subtypes (BL1 and BL2), as well as immunomodulatory (IM), mesenchymal (M), mesenchymal stem cell-like (MSL), and luminal androgen receptor (LAR) subtypes. (cancernetwork.com)
  • Orion Corporation (Nasdaq Helsinki: ORNAV and ORNBV) and Bayer have agreed to start in 2016 a new Phase III study with oral androgen receptor antagonist ODM-201 (BAY-1841788). (orion.fi)
  • Castration of normal male mice induces expansion of the bone marrow B cell population, an effect that can be reversed by androgen replacement. (jci.org)
  • Androgens also exert effects on B cell development in bone marrow. (jci.org)
  • Key topics discussed are the brief history of AAS, epidemiology, methods, and patterns of AAS use, androgen physiology and ergogenic effects, side effects of AAS, and clinical uses of AAS (see Box 1). (lww.com)
  • Vinclozolin (Vin CAS 50471-44-8), a dicarboximide fungicide , has been reported be an antagonist of androgen receptor binding in rats, effects that could result in decreased fertility, defects in reproductive organs or cancer. (cdc.gov)
  • It is also under development in a higher concentration for the treatment of androgen-dependent scalp hair loss, under the brand name Breezula. (wikipedia.org)
  • And if hyperandrogenism drives the microbial composition of the gut, "it would be interesting to determine if treatment of PCOS with androgen antagonists or oral contraceptives results in recovery of the gut microbiome and improvement of the PCOS metabolic phenotype," they note. (medscape.com)
  • Tyagi R.K. Investigation into androgen-independent activation of androgen receptor in prostate cancer. (jnu.ac.in)